1
|
Kitagawa C, Mori M, Ichiki M, Sukoh N, Kada A, Saito AM, Ichinose Y. Gefitinib Plus Bevacizumab vs. Gefitinib Alone for EGFR Mutant Non-squamous Non-small Cell Lung Cancer. In Vivo 2019; 33:477-482. [PMID: 30804129 DOI: 10.21873/invivo.11498] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2018] [Revised: 12/21/2018] [Accepted: 12/27/2018] [Indexed: 01/25/2023]
Abstract
BACKGROUND/AIM A phase II trial was conducted to assess the efficacy and safety of gefitinib plus bevacizumab for EGFR mutation-positive non-small cell lung cancer (NSCLC). PATIENTS AND METHODS Patients were randomly assigned to receive either gefitinib at 250 mg/day alone or with bevacizumab at 15 mg/kg every 3 weeks. RESULTS Ten patients were allocated to the gefitinib group (group A) and 6 to the gefitinib plus bevacizumab group (group B). Median survival time (80%CI) for progression-free survival (PFS) was 15.1 months for group A, and 5.4 months for group B. Overall survival probability at 1 year (95%CI) was 0.750 for group A, and 0.667 for group B. The response rate was 44 % for group A and 50 % for group B. Adverse events occurred at a similar frequency in both groups. CONCLUSION PFS was shorter in group B than group A, and therefore there was no basis to proceed to a phase III trial.
Collapse
Affiliation(s)
- Chiyoe Kitagawa
- Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
| | - Masahide Mori
- Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Toyonaka, Japan
| | - Masao Ichiki
- Department of Respiratory Medicine, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
| | - Noriaki Sukoh
- Department of Respiratory Medicine, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan
| | - Akiko Kada
- Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
| | - Akiko M Saito
- Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
| | - Yukito Ichinose
- Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
| |
Collapse
|
2
|
Fukuda M, Kitazaki T, Ogawara D, Ichiki M, Mukae H, Maruyama R, Nakagaki N, Shimada M, Ikeda T, Kishimoto J, Harada T, Seto T, Ebi N, Takayama K, Okamoto I, Ichinose Y, Sugio K. Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201). Lung Cancer 2019; 132:1-8. [PMID: 31097081 DOI: 10.1016/j.lungcan.2019.01.008] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2018] [Revised: 01/16/2019] [Accepted: 01/20/2019] [Indexed: 11/28/2022]
Abstract
OBJECTIVES To evaluate the efficacy and safety, we conducted a randomized phase II study of pemetrexed (Pem) versus Pem + bevacizumab (Bev) for elderly patients with non-squamous non-small cell lung cancer (NSqNSCLC). PATIENTS AND METHODS The eligibility criteria were as follows: NSqNSCLC, no prior therapy, stage IIIB/IV disease or postoperative recurrence, age: ≥75 years, performance status (PS): 0-1, and adequate bone marrow function. The patients were randomly assigned (1:1 ratio) to receive Pem or Pem + Bev. The primary endpoint was progression-free survival (PFS). The secondary endpoints were the response rate, OS, toxicities, and cost-effectiveness. RESULTS Forty-one patients were enrolled and 40 (20 from each group) were assessable. Their characteristics were as follows: male/female = 23/17; median age (range) = 78 (75-83); stage IIIB/IV/postoperative recurrence = 1/30/9; PS 0/1 = 11/29. All cases involved adenocarcinoma. There was no significant intergroup difference in PFS and the median PFS (95% confidence interval) values of the Pem and Pem + Bev groups were 5.4 (3.0-7.4) and 5.5 (3.6-9.9) months, respectively (p = 0.66). The response rate was significantly higher in the Pem + Bev group (15% vs. 55%, p = 0.0146), and there was no significant difference in OS (median: 16.0 vs. 16.4 months, p = 0.58). Grade 3 and 4 leukopenia, neutropenia, and thrombocytopenia were seen in 10 and 30, 20 and 55, and 5 and 5 cases, respectively. Drug costs were higher in the Pem + Bev group (median: 1,522,008 vs. 3,368,428 JPY, p = 0.01). No treatment-related deaths occurred. CONCLUSIONS Adding Bev to Pem did not result in improved survival in the elderly NSqNSCLC patients. Compared with Pem + Bev, Pem monotherapy had similar effects on survival, a more favorable toxicity profile, and was more cost-effective in elderly NSqNSCLC patients. Pem monotherapy might be one of the optional regimen for NSqNSCLC patients aged ≥75 years.
Collapse
Affiliation(s)
- Minoru Fukuda
- Clinical Oncology Center, Nagasaki University Hospital, Nagasaki, Japan.
| | - Takeshi Kitazaki
- Division of Respiratory Diseases, Department of Internal Medicine, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan
| | - Daiki Ogawara
- Department of Respiratory Medicine, Sasebo City General Hospital, Nagasaki, Japan
| | - Masao Ichiki
- Department of Respirology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
| | - Hiroshi Mukae
- Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | | | - Noriaki Nakagaki
- Department of Respiratory Medicine, Steel Memorial Yawata Hospital, Kitakyushu, Japan
| | - Midori Shimada
- Division of Respiratory Diseases, Department of Internal Medicine, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan; Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - Takaya Ikeda
- Department of Respiratory Medicine, Sasebo City General Hospital, Nagasaki, Japan; Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - Junji Kishimoto
- Center for Clinical and Translational Research, Kyushu University, Fukuoka, Japan
| | - Taishi Harada
- Department of Respiratory Medicine, Japan Community Health Care Organization (JCHO) Kyushu Hospital, Kitakyushu, Japan
| | - Takashi Seto
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | - Noriyuki Ebi
- Department of Respiratory Oncology Medicine, Iizuka Hospital, Fukuoka, Japan
| | - Koichi Takayama
- Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Isamu Okamoto
- Research Institute for Disease of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Yukito Ichinose
- Clinical Research Institute, National Kyushu Cancer Center, Fukuoka, Japan
| | - Kenji Sugio
- Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Oita, Japan; Lung Oncology Group in Kyushu (LOGiK), Fukuoka, Japan
| |
Collapse
|
3
|
Sugawara S, Nakagawa K, Yamamoto N, Nokihara H, Ohe Y, Nishio M, Takahashi T, Goto K, Maemondo M, Ichinose Y, Seto T, Sakai H, Gemma A, Imamura F, Shingyoji M, Saka H, Inoue A, Takeda K, Okamoto I, Kiura K, Morita S, Tamura T. Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC. Int J Clin Oncol 2019; 24:485-493. [PMID: 30830659 PMCID: PMC6469651 DOI: 10.1007/s10147-019-01396-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2018] [Accepted: 12/30/2018] [Indexed: 01/15/2023]
Abstract
Introduction The East Asia S-1 Trial in Lung Cancer (EAST-LC) was a randomized phase III study conducted in East Asia that demonstrated the non-inferiority of S-1 to docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). Here, we reported the results of the Japanese subgroup treated with docetaxel 60 mg/m2, the standard dosage in Japan. Patients and methods Patients were randomized 1:1 to receive either S-1 or docetaxel. The primary endpoint was overall survival (OS); the secondary endpoints included progression-free survival (PFS), response rate (RR), quality of life (QOL), and safety. Results Patient characteristics in the Japanese subgroup (n = 724) were similar to those in the overall EAST-LC population. Median OS was 13.4 months in the S-1 group and 12.6 months in the docetaxel group. In pemetrexed-pretreated patients, OS with S-1 was similar to that with docetaxel. Median PFS was 2.9 and 3.0 months in the S-1 and docetaxel groups, respectively. RR was 9.4% and 10.3% in the S-1 and docetaxel groups, respectively. The QOL of patients treated with S-1 was better compared with that of patients treated with docetaxel. Decreased appetite and diarrhea were more common in the S-1 group, whereas the frequency of neutropenia and febrile neutropenia was markedly higher in the docetaxel group. Conclusions This Japanese subgroup analysis showed that S-1 had similar efficacy to docetaxel in patients with previously treated advanced NSCLC. These results are similar to those of the overall EAST-LC population. Electronic supplementary material The online version of this article (10.1007/s10147-019-01396-z) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Shunichi Sugawara
- Department of Pulmonary Medicine, Sendai Kousei Hospital, Miyagi, Japan
| | - Kazuhiko Nakagawa
- Department of Medical Oncology, Faculty of Medicine, Kindai University, Osaka, Japan
| | - Nobuyuki Yamamoto
- Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan
| | - Hiroshi Nokihara
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Yuichiro Ohe
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Makoto Nishio
- Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | | | - Koichi Goto
- Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
| | - Makoto Maemondo
- Department of Respiratory Medicine, Miyagi Cancer Center, Miyagi, Japan
| | - Yukito Ichinose
- Department of Cancer Information Research, National Kyushu Cancer Center, Clinical Research Institute, Fukuoka, Japan
| | - Takashi Seto
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | - Hiroshi Sakai
- Department of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan
| | - Akihiko Gemma
- Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
| | - Fumio Imamura
- Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan
| | | | - Hideo Saka
- Department of Respiratory Medicine and Medical Oncology, National Hospital Organization Nagoya Medical Center, Aichi, Japan
| | - Akira Inoue
- Department of Palliative Medicine, Tohoku University School of Medicine, Miyagi, Japan
| | - Koji Takeda
- Department of Medical Oncology, Osaka City General Hospital, Osaka, Japan
| | - Isamu Okamoto
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Katsuyuki Kiura
- Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Okayama, Japan
| | - Satoshi Morita
- Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Tomohide Tamura
- Thoracic Center, St Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan.
| |
Collapse
|
4
|
Kitagawa C, Kada A, Saito AM, Ichinose Y, Saka H. Rationale and Design of a Randomized Phase 2 Trial of Gefitinib Plus Bevacizumab vs Gefitinib Alone in Patients with Epidermal Growth Factor Receptor Mutant Non-Squamous Non-Small-Cell Lung Cancer: Study Protocol. Kurume Med J 2018; 65:77-81. [PMID: 30429415 DOI: 10.2739/kurumemedj.ms652001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Combination chemotherapy with platinum preparations is the standard first-line treatment for stage IIIB/IV non-small-cell lung cancer. However, the median survival in patients receiving this therapy is 8 to 10 months, and it is essential to improve the results of chemotherapy in non-small-cell lung cancer. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors hinder EGFR signal transmission by binding to the adenosine triphosphate binding site of intracellular tyrosine kinase and inhibiting the autophospholylation of EGFR. They are a standard initial treatment option in EGFR gene mutation-positive patients. In Japan, gefitinib is routinely used. A combination of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and another antineoplastic drug may be a strategy to further improve treatment outcomes. We planned a randomized phase 2 trial to assess the efficacy and safety of gefitinib plus bevacizumab in such patients. In this study, subjects will be assigned to receive monotherapy with gefitinib (GEF group) or combination therapy with gefitinib and beva cizumab (GEF+BEV group) as the initial treatment at a ratio of 1:1. EGFR gene mutations are frequently detected in Asian patients with non-small-cell lung cancer. This study may be significant for establishing a new standard treatment.
Collapse
Affiliation(s)
- Chiyoe Kitagawa
- Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center
| | - Akiko Kada
- Clinical Research Center, National Hospital Organization Nagoya Medical Center
| | - Akiko M Saito
- Clinical Research Center, National Hospital Organization Nagoya Medical Center
| | - Yukito Ichinose
- Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center
| | - Hideo Saka
- Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center
| |
Collapse
|
5
|
Nosaki K, Umeyama Y, Toyozawa R, Takamori S, Haratake N, Miura N, Oba T, Yamaguchi M, Seto T, Takenoyama M, Ichinose Y. P3.01-76 Clinical Background and Response to Chemotherapy in NSCLC Patients with MET Exon14 Skipping Mutation or High MET Gene Copy Number. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1636] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
6
|
Yamagami K, Matsumoto H, Hashimoto T, Yanai S, Yuen S, Yata Y, Ichinose Y, Deai T, Toi M. The application of indocyanine green fluorescence navigation method to a sentinel lymph node biopsy after neoadjuvant chemotherapy in node-positive breast cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy270.255] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
7
|
Maruyama R, Fukuda M, Kitazaki T, Ogawara D, Ichiki M, Mukae H, Nakagaki N, Kishimoto J, Ichinose Y, Sugio K. P1.01-65 PII of Pemetrexed or Pemetrexed Plus Bevacizumab for Previously Untreated Elderly (>=75) Non-Squamous NSCLC (LOGIK1201). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.621] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
8
|
Sasaki T, Seto T, Yamanaka T, Kunitake N, Shimizu J, Kodaira T, Nishio M, Kozuka T, Takahashi T, Harada H, Yoshimura N, Tsutsumi S, Kitajima H, Kataoka M, Ichinose Y, Nakagawa K, Nishimura Y, Yamamoto N, Nakanishi Y. A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L. Br J Cancer 2018; 119:675-682. [PMID: 30206369 PMCID: PMC6173687 DOI: 10.1038/s41416-018-0243-2] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2018] [Revised: 07/18/2018] [Accepted: 08/02/2018] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND Cisplatin-based chemoradiotherapy is the standard treatment for unresectable, locally advanced non-small-cell lung cancer (NSCLC). This trial evaluated two experimental regimens that combine chemotherapy with concurrent radiotherapy. METHODS Eligible patients with unresectable stage III NSCLC were randomised to either the SP arm (S-1 and cisplatin) or VP arm (vinorelbine and cisplatin), with early concurrent thoracic radiotherapy of 60 Gy, comprising 2 Gy per daily fraction. The primary endpoint was the overall survival rate at 2 years (2-year overall survival (OS)) (Study ID: UMIN000002420). RESULTS From September 2009 to September 2012, 112 patients were enroled. Of the 108 eligible patients, the 2-year OS was 75.6% (80% confidence interval (CI), 67-82%) in the SP arm and 68.5% (80% CI: 60-76%) in the VP arm. The hazard ratio (HR) for death between the two arms was 0.85 (0.48-1.49). The median progression-free survival was 14.8 months for the SP arm and 12.3 months for the VP arm with an HR of 0.92 (0.58-1.44). There were four treatment-related deaths in the SP arm and five in the VP arm. CONCLUSIONS The null hypotheses for 2-year OS were rejected in both arms. The West Japan Oncology Group will employ the SP arm as the investigational arm in a future phase III study.
Collapse
Affiliation(s)
- Tomonari Sasaki
- National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan
| | - Takashi Seto
- National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan.
| | - Takeharu Yamanaka
- Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan
| | - Naonobu Kunitake
- National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan
| | - Junichi Shimizu
- Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan
| | - Takeshi Kodaira
- Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan
| | - Makoto Nishio
- Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo, 135-8550, Japan
| | - Takuyo Kozuka
- Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo, 135-8550, Japan
| | - Toshiaki Takahashi
- Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan
| | - Hideyuki Harada
- Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan
| | - Naruo Yoshimura
- Osaka City University Hospital, 1-5-7 Asahi-machi, Abeno-ku, Osaka, 545-8586, Japan
| | - Shinichi Tsutsumi
- Osaka City University Hospital, 1-5-7 Asahi-machi, Abeno-ku, Osaka, 545-8586, Japan
| | - Hiromoto Kitajima
- Shikoku Cancer Center, 160 Kou, Minamiumemoto-machi, Matsuyama City, Ehime, 791-0280, Japan
| | - Masaaki Kataoka
- Shikoku Cancer Center, 160 Kou, Minamiumemoto-machi, Matsuyama City, Ehime, 791-0280, Japan
| | - Yukito Ichinose
- National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan
| | - Kazuhiko Nakagawa
- Kindai University Hospital, 377-2 Ohnohigashi, Osaka-Sayama, 589-8511, Japan
| | - Yasumasa Nishimura
- Kindai University Hospital, 377-2 Ohnohigashi, Osaka-Sayama, 589-8511, Japan
| | - Nobuyuki Yamamoto
- Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan
| | - Yoichi Nakanishi
- Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan
| |
Collapse
|
9
|
Tamiya A, Koh Y, Kubo A, Ando M, Isa SI, Saka H, Yoshimoto N, Serizawa M, Takeo S, Adachi H, Tagawa T, Kawashima O, Yamashita M, Kataoka K, Ichinose Y, Takeuchi Y, Watanabe K, Matsumura A, Kawaguchi T. Impact of somatic mutations on recurrence free survival (RFS) and overall survival (OS) for resected non-small cell lung cancer (NSCLC): results from the Japan Molecular Epidemiology for lung cancer study (JME). J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.8549] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Akihiro Tamiya
- National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Japan
| | | | - Akihito Kubo
- Division of Respiratory Medicine and Allergology, Aichi Medical University School of Medicine, Nagakute, Japan
| | - Masahiko Ando
- Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan
| | - Shun-ichi Isa
- National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Japan
| | - Hideo Saka
- Department of Respiratory Medicine, Nagoya Medical Center, Nagoya, Japan
| | - Naoki Yoshimoto
- Department of Clinical Oncology, Osaka City University, Graduate School of Medicine, Osaka, Japan
| | - Masakuni Serizawa
- Division of Drug Discovery and Development, Shizuoka Cancer Center Research Institute, Nagaizumi-Cho, Shizuoka, Japan
| | - Sadanori Takeo
- National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
| | - Hirofumi Adachi
- Department of Thoracic Surgery, National Hospital Organization, Hokkaido Cancer Center, Hokkaido, Japan
| | - Tsutomu Tagawa
- National Hospital Organization Nagasaki Medical Center, Omura, Japan
| | - Osamu Kawashima
- National Hospital Organization Shibukawa Medical Center, Shibukawa, Japan
| | | | - Kazuhiko Kataoka
- National Hospital Organization Iwakuni Clinical Center, Iwakuni, Japan
| | - Yukito Ichinose
- National Hospital Organization Kyushu Cancer Center, Fukuoka-Shi, Japan
| | - Yukiyasu Takeuchi
- National Hospital Organization Toneyama National Hospital, Toyonaka, Japan
| | - Katsuya Watanabe
- National Hospital Organization Yokohama Medical Center, Yokohama City, Japan
| | - Akihide Matsumura
- National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan
| | - Tomoya Kawaguchi
- Department of Respiratory Medicine, Osaka City University, Graduate School of Medicine, Osaka, Japan
| |
Collapse
|
10
|
Kogure Y, Saka H, Takiguchi Y, Atagi S, Kurata T, Ebi N, Inoue A, Kubota K, Takenoyama M, Seto T, Kada A, Yamanaka T, Ando M, Yamamoto N, Gemma A, Ichinose Y. A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study Protocol. Clin Lung Cancer 2018; 19:e711-e715. [PMID: 29861395 DOI: 10.1016/j.cllc.2018.05.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2017] [Revised: 05/02/2018] [Accepted: 05/12/2018] [Indexed: 10/16/2022]
Abstract
BACKGROUND Treatment with carboplatin (CBDCA) with weekly paclitaxel (PTX) has shown survival benefits compared with vinorelbine or gemcitabine in elderly patients with non-small-cell carcinoma (NSCLC). Docetaxel (DOC), however, remains a standard treatment in NSCLC. The 130-nm albumin-bound formulation of PTX (nab-PTX) has shown activity in NSCLC. Treatment with CBDCA with weekly nab-PTX showed significantly higher efficacy than CBDCA with PTX in patients with squamous histology and significantly increased overall survival (OS) in patients aged 70 years and older. PATIENTS AND METHODS This randomized, multicenter, phase III trial (UMIN000019843) was designed to compare the efficacy and safety of CBDCA with nab-PTX with DOC in patients aged 70 years and older with advanced squamous NSCLC. Elderly patients who have received no previous chemotherapy for advanced/metastatic squamous NSCLC with Eastern Cooperative Oncology Group performance status of 0 or 1 will be randomized 1:1 to DOC (60 mg/m2 intravenous [I.V.] on day 1) or CBDCA (area under the blood concentration time curve 6 on day 1) with nab-PTX (100 mg/m2 I.V. on days 1, 8, and 15) of each 21-day cycle. The primary end point is OS. Recruitment began in December 2015 and planned enrollment is 250 patients. CONCLUSION If OS is greater in patients treated with CBDCA with nab-PTX than with DOC, this study will provide a new standard of care for elderly patients with squamous NSCLC.
Collapse
Affiliation(s)
- Yoshihito Kogure
- Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Aichi, Japan.
| | - Hideo Saka
- Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Aichi, Japan
| | - Yuichi Takiguchi
- Department of Medical Oncology, Chiba University Hospital, Chiba, Japan
| | - Shinji Atagi
- Department of Internal Medicine, National Hospital Organization Kinki-chuo Chest Medical Center, Osaka, Japan
| | - Takayasu Kurata
- Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan
| | - Noriyuki Ebi
- Department of Respiratory Oncology, Iizuka Hospital, Fukuoka, Japan
| | - Akira Inoue
- Department of Palliative Medicine, Tohoku University School of Medicine, Miyagi, Japan
| | - Kaoru Kubota
- Cancer Center and Department of Pulmonary Medicine and Oncology, Nippon Medical School Hospital, Tokyo, Japan
| | - Mitsuhiro Takenoyama
- Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
| | - Takashi Seto
- Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
| | - Akiko Kada
- Clinical Research Center, National Hospital Organization Nagoya Medical Center, Aichi, Japan
| | - Takeharu Yamanaka
- Department of Biostatistics, Yokohama City University, Kanagawa, Japan
| | - Masahiko Ando
- Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Aichi, Japan
| | - Nobuyuki Yamamoto
- Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan
| | - Akihiko Gemma
- Department of Respiratory Medicine, Nippon Medical School Hospital, Tokyo, Japan
| | - Yukito Ichinose
- Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
| |
Collapse
|
11
|
Haratake N, Takenoyama M, Edagawa M, Shimamatsu S, Toyozawa R, Nosaki K, Hirai F, Yamaguchi M, Taguchi K, Seto T, Ichinose Y. A case of different EGFR mutations in surgically resected synchronous triple lung cancer. J Thorac Dis 2018; 10:E255-E259. [PMID: 29850164 DOI: 10.21037/jtd.2018.03.105] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
We describe a 77-year-old Japanese woman who presented with three nodule shadows in three different lobes of the right lung, without evidence of lymph node metastasis or distant metastasis. All three tumors were surgically resected. The pathological diagnosis was synchronous multiple primary lung cancer: pT2aN0M0, pStageIB. Based on a differing epidermal growth factor receptor (EGFR) mutation status, no lymph node metastasis, and no distant metastasis, the tumors were characterized as synchronous triple primary rather than intrapulmonary metastases. At eight months after surgery, a new lesion emerged in the right lower lobe. Given that the most advanced tumor had an EGFR del-19 mutation, the patient was orally administered afatinib. Since then, the treatment response of the patient has been assessed as stable disease (SD) for about two years. This is a very rare case of resected triple synchronous primary lung cancer on the same lung side in which the lesions all had a different EGFR mutation status, and this report highlights the clinical utility of surgical resection of multifocal lung nodules without lymph node metastasis or distant metastasis in order to optimize therapy for patients with known driver mutations.
Collapse
Affiliation(s)
- Naoki Haratake
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
| | - Mitsuhiro Takenoyama
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
| | - Makoto Edagawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
| | - Shinichiro Shimamatsu
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
| | - Ryo Toyozawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
| | - Kaname Nosaki
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
| | - Fumihiko Hirai
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
| | - Masafumi Yamaguchi
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
| | - Kenichi Taguchi
- Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - Takashi Seto
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
| | - Yukito Ichinose
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
| |
Collapse
|
12
|
Kometani T, Sugio K, Osoegawa A, Seto T, Ichinose Y. Clinicopathological features of younger (aged ≤ 50 years) lung adenocarcinoma patients harboring the EML4-ALK fusion gene. Thorac Cancer 2018. [PMID: 29517858 PMCID: PMC5928374 DOI: 10.1111/1759-7714.12616] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Background The EML4‐ALK fusion gene has recently been identified as a driver mutation in a subset of non‐small cell lung cancers. In subsequent studies, EML4‐ALK has been detected in a low percentage of patients, and was associated with a lack of EGFR or KRAS mutations, younger age, and adenocarcinoma with acinar histology. Cases with the EML4‐ALK fusion gene were examined to clarify the clinicopathological characteristics of young adenocarcinoma patients. Methods Between December 1998 and May 2009, 85 patients aged ≤ 50 with lung adenocarcinoma were treated at our hospital. We examined 49 samples from adenocarcinoma patients who underwent surgical resection, chemotherapy, and/or radiotherapy for the EML4‐ALK gene. None of the patients received ALK inhibitors because these drugs had not been approved in Japan before 2012. EML4‐ALK fusion genes were screened using multiplex reverse‐transcription PCR assay, and were confirmed by direct sequencing. Results The EML4‐ALK fusion gene was detected in five tumors (10.2%). One patient had stage IB disease, one had stage IIIA, and three had stage IV. Histologically, there was one solid adenocarcinoma, two acinar adenocarcinomas, and two papillary adenocarcinomas. EML4‐ALK fusion genes were mutually exclusive to EGFR and KRAS mutations. The five‐year survival rate was 59.4% in patients without EML4‐ALK fusion and was not reached in patients with EML4‐ALK fusion. Conclusion The EML4‐ALK fusion gene may be a strong oncogene in younger patients with lung adenocarcinoma.
Collapse
Affiliation(s)
- Takuro Kometani
- Department of Thoracic Oncology and Clinical Research Institute, National Kyushu Cancer Center, Fukuoka, Japan.,Department of Thoracic Surgery, Saiseikai Fukuoka General Hospital, Fukuoka, Japan
| | - Kenji Sugio
- Department of Thoracic Oncology and Clinical Research Institute, National Kyushu Cancer Center, Fukuoka, Japan.,Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Oita, Japan
| | - Atsushi Osoegawa
- Department of Thoracic Oncology and Clinical Research Institute, National Kyushu Cancer Center, Fukuoka, Japan.,Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Oita, Japan
| | - Takashi Seto
- Department of Thoracic Oncology and Clinical Research Institute, National Kyushu Cancer Center, Fukuoka, Japan
| | - Yukito Ichinose
- Department of Thoracic Oncology and Clinical Research Institute, National Kyushu Cancer Center, Fukuoka, Japan
| |
Collapse
|
13
|
Takamori S, Toyokawa G, Shimokawa M, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Hirai F, Seto T, Tagawa T, Takenoyama M, Ichinose Y, Maehara Y. The C-Reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma: A Retrospective Multi-institutional Study. Ann Surg Oncol 2018; 25:1555-1563. [PMID: 29500763 DOI: 10.1245/s10434-018-6385-x] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2017] [Indexed: 12/15/2022]
Abstract
BACKGROUND Malignant pleural mesothelioma (MPM), a devastating neoplasm, is traditionally considered to be resistant to antitumor therapy. Identification of clinical prognostic indicators is therefore needed. Although the C-reactive protein/albumin ratio (CAR) has been used to predict the prognosis of many types of malignancy, its utility in patients with MPM is unknown. METHODS The data of 100 patients diagnosed as having MPM from 1995 to 2015 at the National Kyushu Cancer Center and Kyushu University were analyzed. The CAR was calculated as serum C-reactive protein concentration divided by albumin concentration. A cutoff for CAR was set at 0.58 according to a receiver operating characteristics curve for 1-year survival. RESULTS Thirty-five of the 100 (35.0%) patients were classified as having a high CAR. A high CAR was significantly associated with advanced clinical stage (p < 0.001) and chemotherapy alone (p = 0.002). Patients with a high CAR had significantly shorter overall survival (OS) (p < 0.001) and disease- or progression-free survival (DFS/PFS) (p < 0.001). These associations between CAR and prognosis remained significant after propensity score-matching. In multivariate analysis, a high CAR was an independent predictor of shorter OS and DFS/PFS (p = 0.003 and p = 0.008, respectively). Multivariate analyses of the subgroups of patients who had received chemotherapy and of patients who had undergone surgery also showed that a high CAR was an independent predictor of shorter OS and DFS/PFS. CONCLUSIONS CAR is an independent predictor of prognosis in MPM patients. This prognostic index contributes to clinicians' ability to predict benefit from treatment. Further larger, prospective studies are necessary to validate these findings.
Collapse
Affiliation(s)
- Shinkichi Takamori
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.,Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | - Gouji Toyokawa
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Mototsugu Shimokawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | - Fumihiko Kinoshita
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Yuka Kozuma
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Taichi Matsubara
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Naoki Haratake
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Takaki Akamine
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Fumihiko Hirai
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Takashi Seto
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | - Tetsuzo Tagawa
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | | | - Yukito Ichinose
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | - Yoshihiko Maehara
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| |
Collapse
|
14
|
Soo R, Mok T, Shi YK, Zhang L, Lu S, Yang JCH, Nakagawa K, Yamamoto N, Nokihara H, Sugawara S, Nishio M, Takahashi T, Goto K, Chang J, Maemondo M, Ichinose Y, Cheng Y, Lim W, Morita S, Tamura T. EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel (DOC) in patients with non-small cell lung cancer (NSCLC) who had received a platinum-based treatment: Results from patient-reported outcomes (PROs). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx671.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Seto T, Nosaki K, Toyozawa R, Taguchi K, Edagawa M, Shimamatsu S, Toyokawa G, Hirai F, Yamaguchi M, Takeda Y, Takenoyama M, Ichinose Y. Real-world data on treatment patterns and survival among ALK+ NSCLC patients in Japan. Treatment patterns and survival among ALK+ NSCLC patients in Japan: Single institute experience. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx671.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Nokihara H, Lu S, Mok TSK, Nakagawa K, Yamamoto N, Shi YK, Zhang L, Soo RA, Yang JC, Sugawara S, Nishio M, Takahashi T, Goto K, Chang J, Maemondo M, Ichinose Y, Cheng Y, Lim WT, Morita S, Tamura T. Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). Ann Oncol 2017; 28:2698-2706. [PMID: 29045553 PMCID: PMC5834128 DOI: 10.1093/annonc/mdx419] [Citation(s) in RCA: 64] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND Chemotherapy remains a viable option for the management of advanced non-small-cell lung cancer (NSCLC) despite recent advances in molecular targeted therapy and immunotherapy. We evaluated the efficacy of oral 5-fluorouracil-based S-1 as second- or third-line therapy compared with standard docetaxel therapy in patients with advanced NSCLC. PATIENTS AND METHODS Patients with advanced NSCLC previously treated with ≥1 platinum-based therapy were randomized 1 : 1 to docetaxel (60 mg/m2 in Japan, 75 mg/m2 at all other study sites; day 1 in a 3-week cycle) or S-1 (80-120 mg/day, depending on body surface area; days 1-28 in a 6-week cycle). The primary endpoint was overall survival. The non-inferiority margin was a hazard ratio (HR) of 1.2. RESULTS A total of 1154 patients (577 in each arm) were enrolled, with balanced patient characteristics between the two arms. Median overall survival was 12.75 and 12.52 months in the S-1 and docetaxel arms, respectively [HR 0.945; 95% confidence interval (CI) 0.833-1.073; P = 0.3818]. The upper limit of 95% CI of HR fell below 1.2, confirming non-inferiority of S-1 to docetaxel. Difference in progression-free survival between treatments was not significant (HR 1.033; 95% CI 0.913-1.168; P = 0.6080). Response rate was 8.3% and 9.9% in the S-1 and docetaxel arms, respectively. Significant improvement was observed in the EORTC QLQ-C30 global health status over time points in the S-1 arm. The most common adverse drug reactions were decreased appetite (50.4%), nausea (36.4%), and diarrhea (35.9%) in the S-1 arm, and neutropenia (54.8%), leukocytopenia (43.9%), and alopecia (46.6%) in the docetaxel arm. CONCLUSION S-1 is equally as efficacious as docetaxel and offers a treatment option for patients with previously treated advanced NSCLC. CLINICAL TRIAL NUMBER Japan Pharmaceutical Information Center, JapicCTI-101155.
Collapse
Affiliation(s)
- H Nokihara
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - S Lu
- Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai
| | - T S K Mok
- Department of Clinical Oncology, State Key Laboratory in Oncology in South China, The Chinese University of Hong Kong, Hong Kong, China.
| | - K Nakagawa
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka
| | - N Yamamoto
- Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan
| | - Y K Shi
- Department of Medical Oncology, National Cancer Center/Cancer Hospital Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing
| | - L Zhang
- Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China
| | - R A Soo
- Department of Hematology-Oncology, National University Hospital, Cancer Science Institute of Singapore, Singapore
| | - J C Yang
- Department of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan
| | - S Sugawara
- Department of Pulmonary Medicine, Sendai Kousei Hospital, Miyagi
| | - M Nishio
- Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo
| | - T Takahashi
- Department of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka
| | - K Goto
- Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan
| | - J Chang
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
| | - M Maemondo
- Department of Thoracic Oncology, Miyagi Cancer Center, Miyagi
| | - Y Ichinose
- Department of Cancer Information Research, National Kyushu Cancer Center, Clinical Research Institute, Fukuoka, Japan
| | - Y Cheng
- Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun, China
| | - W T Lim
- Department of Medical Oncology, National Cancer Center Singapore, Singapore
| | - S Morita
- Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto
| | - T Tamura
- Thoracic Center, St Luke's International Hospital, Tokyo, Japan
| |
Collapse
|
17
|
Takamori S, Toyokawa G, Tagawa T, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Hirai F, Takenoyama M, Ichinose Y, Maehara Y. P2.09-005 The C-reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
18
|
Yamaguchi M, Hirai F, Taguchi K, Toyozawa R, Edagawa M, Shimamatsu S, Nosaki K, Seto T, Takenoyama M, Ichinose Y. A typical carcinoid tumor of the lung presenting with pure persistent ground-glass opacity on high-resolution computed tomography: a case report. Surg Case Rep 2017; 3:108. [PMID: 28980178 PMCID: PMC5628087 DOI: 10.1186/s40792-017-0382-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2017] [Accepted: 09/21/2017] [Indexed: 11/22/2022] Open
Abstract
Pure ground-glass opacity nodules (p-GGN) on high-resolution computed tomography (HRCT) generally have been considering typically associated with adenocarcinoma with less invasive nature. We herein reported a patient presenting focal p-GGN on middle lobe of the right lung who underwent surgical resection with its pathological diagnosis turned out to be typical carcinoid tumor.
Collapse
Affiliation(s)
- Masafumi Yamaguchi
- Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka, 811-1395, Japan.
| | - Fumihiko Hirai
- Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka, 811-1395, Japan
| | - Kenichi Taguchi
- Department of Pathology, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka, 811-1395, Japan
| | - Ryo Toyozawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka, 811-1395, Japan
| | - Makoto Edagawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka, 811-1395, Japan
| | - Shinichiro Shimamatsu
- Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka, 811-1395, Japan
| | - Kaname Nosaki
- Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka, 811-1395, Japan
| | - Takashi Seto
- Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka, 811-1395, Japan
| | - Mitsuhiro Takenoyama
- Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka, 811-1395, Japan
| | - Yukito Ichinose
- Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka, 811-1395, Japan
| |
Collapse
|
19
|
Shindo K, Sato T, Satake A, Kurita N, Tsuchiya M, Ichinose Y, Hata T, Koh K, Yamashiro N, Kobayashi F, Nagasaka T, Takiyama Y. Skin vasomotor regulation in patients with multiple system atrophy. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
20
|
Nagasaka T, Hata T, Ichinose Y, Kho K, Yamashiro N, Tsuchiya M, Takaki R, Shindo K, Takiyama Y. Morphological features of mitochondria in anti-mitochondrial antibodies-positive myositis. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
21
|
Saka H, Kitagawa C, Ichinose Y, Takenoyama M, Ibata H, Kato T, Takami K, Yamashita M, Maeda T, Takeo S, Ueda H, Okabayashi K, Nagashima S, Oka T, Kouso H, Fukuyama S, Yoshimoto K, Shimokawa M, Saito AM, Ito S. A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II-IIIA non-small cell lung cancer: study protocol for a randomized controlled trial. Trials 2017; 18:429. [PMID: 28915900 PMCID: PMC5603008 DOI: 10.1186/s13063-017-2103-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2016] [Accepted: 07/12/2017] [Indexed: 11/10/2022] Open
Abstract
Background As the toxicity associated with the α-GalCer-pulsed dendritic cell (DC) therapy could be considered to be negligible, its addition to postoperative adjuvant chemotherapy would be expected to greatly improve the therapeutic effect, and could result in prolonged survival. The aim of the present study is to compare the therapeutic efficacy of alpha-galactosylceramide-pulsed DC therapy in patients who have undergone a complete resection of stage II–IIIA non-small-cell lung cancer (NSCLC) followed by postoperative adjuvant therapy with cisplatin plus vinorelbine, to that in patients who did not receive additional treatment (surgical resection plus postoperative adjuvant chemotherapy only). Methods Subsequent to the complete resection of NSCLC, followed by the administration of cisplatin plus vinorelbine dual-agent combination adjuvant chemotherapy, patients who satisfy the inclusion criteria will be randomly allocated to either the α-GalCer-pulsed DC immune therapy group, or the standard treatment group. In total, 56 patients will be included in the study. The primary endpoint is recurrence-free survival, and the secondary endpoints are natural killer T-cell-specific immune response, the frequency of toxic effects and safety, and overall survival. Discussion In order to determine the efficacy of α-GalCer-pulsed DC therapy, the present study compares patients with stage II–III NSCLC who underwent complete surgical resection followed by postoperative adjuvant therapy with cisplatin plus vinorelbine, to those who did not receive additional treatment (surgical resection plus postoperative adjuvant chemotherapy only). Trial registration UMIN000010386 (R000012145). Registered on 1 April 2013. UMIN-CTR is officially recognized as a registration site which satisfies ICMJE criteria. Electronic supplementary material The online version of this article (doi:10.1186/s13063-017-2103-4) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Hideo Saka
- Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Aichi, Japan. .,Clinical Research Center, National Hospital Organization Nagoya Medical Center, Aichi, Japan. .,, 4-1-1 Sannomaru, Naka-ku, Nagoya, 460-0001, Japan.
| | - Chiyoe Kitagawa
- Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Aichi, Japan.,Clinical Research Center, National Hospital Organization Nagoya Medical Center, Aichi, Japan
| | - Yukito Ichinose
- Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
| | - Mitsuhiro Takenoyama
- Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
| | - Hidenori Ibata
- Department of Respiratory Medicine, National Hospital Organization Mie Chuo Medical Center, Mie, Japan
| | - Tatsuo Kato
- Department of Respiratory Medicine, National Hospital Organization Nagara Medical Center, Gifu, Japan
| | - Koji Takami
- Department of Respiratory Medicine, National Hospital Organization Osaka Medical Center, Osaka, Japan
| | - Motohiro Yamashita
- Department of Thoracic Surgery, National Hospital Organization Shikoku Cancer Center, Ehime, Japan
| | - Tadashi Maeda
- Department of Medical Oncology, National Hospital Organization Yamaguchi Ube Medical Center, Yamaguchi, Japan
| | - Sadanori Takeo
- Department of Thoracic Surgery, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
| | - Hitoshi Ueda
- Department of Surgery, National Hospital Organization Fukuoka Hospital, Fukuoka, Japan
| | - Kan Okabayashi
- Department of Thoracic Surgery, National Hospital Organization Fukuoka Higashi Medical Center, Fukuoka, Japan
| | - Seiji Nagashima
- Department of Respiratory Medicine, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan
| | - Tadayuki Oka
- Department of Surgery, National Hospital Organization Ureshino Medical Center, Saga, Japan
| | - Hidenori Kouso
- Department of Thoracic Surgery, National Hospital Organization Oita Medical Center, Oita, Japan
| | - Seiichi Fukuyama
- Department of Thoracic Surgery, National Hospital Organization Beppu Medical Center, Oita, Japan
| | - Kentaro Yoshimoto
- Department of Thoracic Surgery, National Hospital Organization Minami Kyushu National Hospital, Kagoshima, Japan
| | - Mototsugu Shimokawa
- Clinical Research Center, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
| | - Akiko M Saito
- Clinical Research Center, National Hospital Organization Nagoya Medical Center, Aichi, Japan
| | - Suminobu Ito
- Clinical Research Center, National Hospital Organization, Tokyo, Japan
| |
Collapse
|
22
|
Kubota K, Yoshioka H, Oshita F, Hida T, Yoh K, Hayashi H, Kato T, Kaneda H, Yamada K, Tanaka H, Ichinose Y, Park K, Cho EK, Lee KH, Lin CB, Yang JCH, Hara K, Asato T, Nakagawa K. Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 2017; 35:3662-3670. [PMID: 28902534 DOI: 10.1200/jco.2017.72.7297] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
Purpose This phase III, randomized, placebo-controlled, double-blind study determined whether motesanib improved progression-free survival (PFS) compared with placebo in combination with paclitaxel and carboplatin (P/C) in East Asian patients with stage IV/recurrent nonsquamous non-small-cell lung cancer. Patients and Methods Patients were randomly assigned (1:1) to receive oral motesanib 125 mg or placebo once daily plus paclitaxel 200 mg/m2 IV and carboplatin area under the concentration-time curve 6 mg/mL ⋅ min IV for up to six 3-week cycles. Random assignment was stratified by epidermal growth factor receptor status, region, and weight loss in the 6 months before assignment. The primary end point was PFS, the key secondary end point was overall survival, and other secondary end points were objective response rate, time to tumor response, duration of response, and adverse events (AEs). Results Four hundred one patients were assigned to receive motesanib plus P/C (n = 197) or placebo plus P/C (n = 204). Median PFS was 6.1 v 5.6 months for motesanib versus placebo (stratified log-rank test P = .0825; stratified hazard ratio, 0.81; 95% CI, 0.64 to 1.03; P = .0820); median overall survival was not reached versus 21.6 months ( P = .5514). In secondary analyses, the objective response rate was 60.1% v 41.6% ( P < .001); median time to tumor response, 1.4 v 1.6 months, and median duration of response, 5.3 v 4.1 months. Incidence of grade ≥ 3 AEs (86.7% v 67.6%) and AEs that led to drug discontinuation (32.7% v 14.2%) were higher with motesanib than with placebo. AEs reported more frequently with motesanib were GI disorders, hypertension, and gallbladder related. Conclusion Motesanib plus P/C did not significantly improve PFS versus placebo plus P/C in East Asian patients with stage IV/recurrent nonsquamous non-small-cell lung cancer.
Collapse
Affiliation(s)
- Kaoru Kubota
- Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan University Cancer Center, Taipei City, Peoples Republic of China
| | - Hiroshige Yoshioka
- Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan University Cancer Center, Taipei City, Peoples Republic of China
| | - Fumihiro Oshita
- Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan University Cancer Center, Taipei City, Peoples Republic of China
| | - Toyoaki Hida
- Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan University Cancer Center, Taipei City, Peoples Republic of China
| | - Kiyotaka Yoh
- Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan University Cancer Center, Taipei City, Peoples Republic of China
| | - Hidetoshi Hayashi
- Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan University Cancer Center, Taipei City, Peoples Republic of China
| | - Terufumi Kato
- Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan University Cancer Center, Taipei City, Peoples Republic of China
| | - Hiroyasu Kaneda
- Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan University Cancer Center, Taipei City, Peoples Republic of China
| | - Kazuhiko Yamada
- Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan University Cancer Center, Taipei City, Peoples Republic of China
| | - Hiroshi Tanaka
- Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan University Cancer Center, Taipei City, Peoples Republic of China
| | - Yukito Ichinose
- Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan University Cancer Center, Taipei City, Peoples Republic of China
| | - Keunchil Park
- Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan University Cancer Center, Taipei City, Peoples Republic of China
| | - Eun Kyung Cho
- Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan University Cancer Center, Taipei City, Peoples Republic of China
| | - Kyung-Hee Lee
- Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan University Cancer Center, Taipei City, Peoples Republic of China
| | - Chih-Bin Lin
- Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan University Cancer Center, Taipei City, Peoples Republic of China
| | - James Chih-Hsin Yang
- Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan University Cancer Center, Taipei City, Peoples Republic of China
| | - Kaori Hara
- Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan University Cancer Center, Taipei City, Peoples Republic of China
| | - Takayuki Asato
- Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan University Cancer Center, Taipei City, Peoples Republic of China
| | - Kazuhiko Nakagawa
- Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan University Cancer Center, Taipei City, Peoples Republic of China
| |
Collapse
|
23
|
Edagawa M, Haratake N, Shimamatsu S, Toyozawa R, Nosaki K, Hirai F, Yamaguchi M, Taguchi K, Kaneko K, Seto T, Takenoyama M, Ichinose Y. Surgical resection of a well-differentiated inflammatory liposarcoma of the middle mediastinum: a case report. J Thorac Dis 2017; 9:E689-E693. [PMID: 28932587 DOI: 10.21037/jtd.2017.07.90] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Liposarcomas are the most common type of mesenchymal neoplasm in soft tissue sarcomas. Although they frequently develop at the lower limbs or retroperitoneum, cases arising from the mediastinum are rare. Furthermore, the incidence of the inflammatory subtype of well-differentiated liposarcoma is known to be low. We experienced a case of a middle mediastinal liposarcoma in a 68-year-old woman. The tumor, which was completely resected, was 92 mm in diameter. The tumor consisted of two different imaging components that showed different growth and which were diagnosed as the lipoma-like subtype and inflammatory subtype of well-differentiated liposarcoma. To the best of our knowledge, this is the first report of a well-differentiated inflammatory liposarcoma arising from the middle mediastinum.
Collapse
Affiliation(s)
- Makoto Edagawa
- Department of Thoracic Oncology, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka, Japan
| | - Naoki Haratake
- Department of Thoracic Oncology, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka, Japan
| | - Shinichiro Shimamatsu
- Department of Thoracic Oncology, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka, Japan
| | - Ryo Toyozawa
- Department of Thoracic Oncology, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka, Japan
| | - Kaname Nosaki
- Department of Thoracic Oncology, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka, Japan
| | - Fumihiko Hirai
- Department of Thoracic Oncology, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka, Japan
| | - Masafumi Yamaguchi
- Department of Thoracic Oncology, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka, Japan
| | - Kenichi Taguchi
- Cancer Pathology Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka, Japan
| | - Koichiro Kaneko
- PET Imaging Diagnostic Center, Fukuoka Central General Medical Examination Center, Fukuoka, Japan
| | - Takashi Seto
- Department of Thoracic Oncology, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka, Japan
| | - Mitsuhiro Takenoyama
- Department of Thoracic Oncology, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka, Japan
| | - Yukito Ichinose
- Department of Thoracic Oncology, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka, Japan
| |
Collapse
|
24
|
Watanabe M, Kawaguchi T, Isa SI, Ando M, Tamiya A, Kubo A, Saka H, Takeo S, Adachi H, Tagawa T, Kawashima O, Yamashita M, Kataoka K, Ichinose Y, Takeuchi Y, Watanabe K, Matsumura A, Koh Y. Multiplex Ultrasensitive Genotyping of Patients with Non-Small Cell Lung Cancer for Epidermal Growth Factor Receptor (EGFR) Mutations by Means of Picodroplet Digital PCR. EBioMedicine 2017. [PMID: 28625519 PMCID: PMC5514407 DOI: 10.1016/j.ebiom.2017.06.003] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Epidermal growth factor receptor (EGFR) mutations have been used as the strongest predictor of effectiveness of treatment with EGFR tyrosine kinase inhibitors (TKIs). Three most common EGFR mutations (L858R, exon 19 deletion, and T790M) are known to be major selection markers for EGFR-TKIs therapy. Here, we developed a multiplex picodroplet digital PCR (ddPCR) assay to detect 3 common EGFR mutations in 1 reaction. Serial-dilution experiments with genomic DNA harboring EGFR mutations revealed linear performance, with analytical sensitivity ~0.01% for each mutation. All 33 EGFR-activating mutations detected in formalin-fixed paraffin-embedded (FFPE) tissue samples by the conventional method were also detected by this multiplex assay. Owing to the higher sensitivity, an additional mutation (T790M; including an ultra-low-level mutation, <0.1%) was detected in the same reaction. Regression analysis of the duplex assay and multiplex assay showed a correlation coefficient (R2) of 0.9986 for L858R, 0.9844 for an exon 19 deletion, and 0.9959 for T790M. Using ddPCR, we designed a multiplex ultrasensitive genotyping platform for 3 common EGFR mutations. Results of this proof-of-principle study on clinical samples indicate clinical utility of multiplex ddPCR for screening for multiple EGFR mutations concurrently with an ultra-rare pretreatment mutation (T790M).
Collapse
Affiliation(s)
- Masaru Watanabe
- Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan; Department of Respiratory Medicine and Medical Oncology, National Hospital Organization Nagoya Medical Center, Aichi, Japan
| | - Tomoya Kawaguchi
- Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Osaka, Japan; National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan
| | - Shun-Ichi Isa
- Clinical Research Center, Department of Thoracic Oncology, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan
| | - Masahiko Ando
- Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Aichi, Japan
| | - Akihiro Tamiya
- Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan
| | - Akihito Kubo
- Division of Respiratory Medicine and Allergology, Aichi Medical University School of Medicine, Aichi, Japan; Department of Respiratory Medicine and Medical Oncology, National Hospital Organization Nagoya Medical Center, Aichi, Japan
| | - Hideo Saka
- Department of Respiratory Medicine and Medical Oncology, National Hospital Organization Nagoya Medical Center, Aichi, Japan
| | - Sadanori Takeo
- Department of Thoracic Surgery, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
| | - Hirofumi Adachi
- Department of Thoracic Surgery, National Hospital Organization Hokkaido Cancer Center, Hokkaido, Japan
| | - Tsutomu Tagawa
- Department of Thoracic Surgery, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan
| | - Osamu Kawashima
- Department of Thoracic Surgery, National Hospital Organization Shibukawa Medical Center, Gunma, Japan
| | - Motohiro Yamashita
- Department of Thoracic Surgery, National Hospital Organization Shikoku Cancer Center, Ehime, Japan
| | - Kazuhiko Kataoka
- Department of Thoracic Surgery, National Hospital Organization Iwakuni Clinical Center, Yamaguchi, Japan
| | - Yukito Ichinose
- Clinical Research Institute, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
| | - Yukiyasu Takeuchi
- Department of General Thoracic Surgery, National Hospital Organization Toneyama National Hospital, Osaka, Japan
| | - Katsuya Watanabe
- Department of Thoracic Surgery, National Hospital Organization Yokohama Medical Center, Kanagawa, Japan
| | - Akihide Matsumura
- Department of Surgery, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan
| | - Yasuhiro Koh
- Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan; Department of Respiratory Medicine and Medical Oncology, National Hospital Organization Nagoya Medical Center, Aichi, Japan.
| |
Collapse
|
25
|
Nosaki K, Toyozawa R, Taguchi K, Edagawa M, Shimamatsu SI, Toyokawa G, Hirai F, Yamaguchi M, Takeda Y, Seto T, Takenoyama M, Ichinose Y. Real-world data on treatment patterns and survival among ALK+ NSCLC patients in Japan. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.e20505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e20505 Background: Three ALK inhibitors (ALKi) are approved in Japan for treatment of patients with ALK-positive (ALK+) advanced or metastatic non-small cell lung cancer (NSCLC). However, the optimal sequence of therapy with ALKi is unclear. The objective of this study was to provide real-world data on the treatment patterns and survival among ALK+ NSCLC patients. Methods: ALK+ patients treated with ALKi in our institute were included in this retrospective analysis. Data on the treatment patterns and outcomes were collected from medical records. Results: In total, 60 patients were included. The median age at the diagnosis was 52.5 years, with 60% female and 65% non-smokers. The first treatment was chemotherapy in 67% and ALKi in 33%. The median overall survival (OS) was 186 weeks. We found differences in the OS for Crizotinib use at any line (118 weeks; presence vs. NR; absence) and first-line use of an ALKi (127 weeks; Crizotinib vs. 416 weeks; Alecitinib or Ceritinib, p = 0.0048). Conclusions: The role of Crizotinib in the treatment of ALK+ NSCLC is decreasing. Alectinib followed by Ceritinib seems to be promising. Treatment decision-making based on a re-biopsy is immature at present. The development of sequential therapy with ALKi based on resistance mechanisms is urgently needed. [Table: see text]
Collapse
Affiliation(s)
- Kaname Nosaki
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | - Ryo Toyozawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | - Kenichi Taguchi
- Department of Pathology, National Kyushu Cancer Center, Fukuoka, Japan
| | - Makoto Edagawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | | | - Goji Toyokawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | - Fumihiko Hirai
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | - Masafumi Yamaguchi
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | - Yoko Takeda
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | - Takashi Seto
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | | | - Yukito Ichinose
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| |
Collapse
|
26
|
Hirai F, Edagawa M, Shimamatsu S, Toyozawa R, Toyokawa G, Nosaki K, Yamaguchi M, Seto T, Takenoyama M, Ichinose Y. Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type. Oncol Lett 2017; 14:306-312. [PMID: 28693169 DOI: 10.3892/ol.2017.6118] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2015] [Accepted: 02/07/2017] [Indexed: 01/19/2023] Open
Abstract
Erlotinib is one of the treatment choices for patients with advanced non-small cell lung cancer (NSCLC), regardless of the epidermal growth factor receptor (EGFR) mutation status. However, its efficacy for the treatment of patients with NSCLC with EGFR wild type or who are beyond the usage of gefitinib remains controversial. The present study therefore retrospectively assessed the efficacy of erlotinib in patients with wild type EGFR who had previously undergone gefitinib therapy. A total of 222 patients with NSCLC who received chemotherapeutic treatment with erlotinib between July 2007 and February 2013 were evaluated. The background variables, response rates, progression-free survival (PFS) and overall survival rates were retrospectively analyzed. The male/female ratio of patients was 103/119, and patients had a median age of 63 years (range, 33-95 years). A total of 10 of the 222 patients had clinical stages IIIB/IV, 191 had adenocarcinoma, 5 had large cell carcinoma, 10 had squamous cell carcinoma and 6 had NSCLC of a variety not otherwise specified. The EGFR mutation was positive, wild type or unknown in 95, 52 and 75 patients, respectively. In the 52 patients with EGFR wild type, there were 3 partial responders, 25 with stable disease and 24 with progressive disease, for a response rate of 6% [95% confidence interval (CI), 1.3-15%]. The median PFS of EGFR wild type and positive were 1.1 months (95% CI, 1.04-1.16 months) and 5.42 months (95% CI, 5.43-5.68 months), respectively. The results of the study demonstrated that erlotinib is not sufficiently effective for patients with NSCLC who possess the EGFR wild type status.
Collapse
Affiliation(s)
- Fumihiko Hirai
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
| | - Makoto Edagawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
| | - Shinichiro Shimamatsu
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
| | - Ryo Toyozawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
| | - Gouji Toyokawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
| | - Kaname Nosaki
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
| | - Masafumi Yamaguchi
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
| | - Takashi Seto
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
| | - Mitsuhiro Takenoyama
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
| | - Yukito Ichinose
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
| |
Collapse
|
27
|
Takamori S, Yamaguchi M, Taguchi K, Edagawa M, Shimamatsu S, Toyozawa R, Nosaki K, Hirai F, Seto T, Takenoyama M, Ichinose Y. Uncommon features of surgically resected ALK-positive cavitary lung adenocarcinoma: a case report. Surg Case Rep 2017; 3:46. [PMID: 28321808 PMCID: PMC5359261 DOI: 10.1186/s40792-017-0322-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2017] [Accepted: 03/16/2017] [Indexed: 11/10/2022] Open
Abstract
Some features found on chest computed tomography (CT), such as central tumor location, large pleural effusion, and the absence of a pleural tail, and a patient age of less than 60 years, have been suggested to be useful in predicting anaplastic lymphoma kinase (ALK) rearrangement in patients with non-small cell lung cancer (NSCLC). A 68-year-old female patient with a history of gynecological treatment was found to have a cavitary mass in the right lower lobe on an annual chest roentgenogram. The tumor was located in the peripheral area with a pleural tail showing no pleural effusion. In addition, two pure ground-glass-opacity nodules (p-GGNs) in the right upper lobe of the lung were detected on consecutive chest CT scans. The patient underwent right lower lobectomy, partial resection of the right upper lobe, and hilar mediastinal lymph node dissection for complete resection of each tumor. The pathological diagnosis was invasive mucinous adenocarcinoma with signet-ring cells for the cavitary mass in the right lower lobe and invasive adenocarcinoma for the rest of the p-GGNs; subcarinal lymph node metastasis was also detected. The ALK rearrangement was detected by fluorescence in situ hybridization from the cavitary mass. The patient underwent four cycles of cisplatin and vinorelbine chemotherapy as standard adjuvant chemotherapy for pStage III NSCLC. The ALK fusion gene status of NSCLC with atypical CT features should also be investigated.
Collapse
Affiliation(s)
- Shinkichi Takamori
- Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan
| | - Masafumi Yamaguchi
- Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan.
| | - Kenichi Taguchi
- Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan
| | - Makoto Edagawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan
| | - Shinichiro Shimamatsu
- Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan
| | - Ryo Toyozawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan
| | - Kaname Nosaki
- Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan
| | - Fumihiko Hirai
- Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan
| | - Takashi Seto
- Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan
| | - Mitsuhiro Takenoyama
- Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan
| | - Yukito Ichinose
- Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan
| |
Collapse
|
28
|
Toyokawa G, Taguchi K, Edagawa M, Shimamatsu S, Toyozawa R, Nosaki K, Hirai F, Yamaguchi M, Shimokawa M, Seto T, Takenoyama M, Hamamoto R, Sugio K, Ichinose Y. The Prognostic Impact of Jumonji Domain-containing 2B in Patients with Resected Lung Adenocarcinoma. Anticancer Res 2017; 36:4841-6. [PMID: 27630338 DOI: 10.21873/anticanres.11046] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2016] [Accepted: 07/21/2016] [Indexed: 11/10/2022]
Abstract
BACKGROUND Jumonji domain-containing 2B, JMJD2B, has been shown to play an important role in the pathogenesis of lung cancer cells. However, the significance of JMJD2B in patients with lung cancer remains to be elucidated. PATIENTS AND METHODS Seventy-eight patients with resected adenocarcinoma, whose data regarding oncogenic drivers in lung cancer were available, were included in the study. Immunohistochemical analysis was performed with a specific antibody for JMJD2B to investigate JMJD2B expression and the significance of JMJD2B expression in survival after surgery was evaluated. RESULTS Among the 78 patients, 50 (64%) exhibited JMJD2B immunopositivity. The overall survival (OS) of the 50 JMJD2B-positive patients after surgery was significantly inferior to that of the JMJD2B-negative patients (five-year survival=56.7% vs. 92.6%; log-rank: p=0.01). Multivariate analysis showed that JMJD2B positivity was an independent prognostic factor. CONCLUSION JMJD2B may be a novel prognostic factor for resected lung adenocarcinoma.
Collapse
Affiliation(s)
- Gouji Toyokawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | - Kenichi Taguchi
- Cancer Pathology Laboratory, National Kyushu Cancer Center, Fukuoka, Japan
| | - Makoto Edagawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | | | - Ryo Toyozawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | - Kaname Nosaki
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | - Fumihiko Hirai
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | - Masafumi Yamaguchi
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | | | - Takashi Seto
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | | | - Ryuji Hamamoto
- Division of Molecular Modification and Cancer Biology, National Cancer Center, Tokyo, Japan
| | - Kenji Sugio
- Department of Thoracic and Breast Surgery, Oita University, Oita, Japan
| | - Yukito Ichinose
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| |
Collapse
|
29
|
Fukuda M, Shimada M, Kitazaki T, Nagashima S, Hashiguchi K, Ebi N, Takayama K, Nakanishi Y, Semba H, Harada T, Seto T, Okamoto I, Ichinose Y, Sugio K. Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A). Thorac Cancer 2016; 8:40-45. [PMID: 27883280 PMCID: PMC5217920 DOI: 10.1111/1759-7714.12407] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2016] [Revised: 10/10/2016] [Accepted: 10/12/2016] [Indexed: 11/27/2022] Open
Abstract
Background Various polymorphisms have been detected in the UDP‐glucuronosyltransferase 1A (UGT1A) gene, and UGT1A1*28 and UGT1A1*6 have important effects on the pharmacokinetics of irinotecan and the risk of severe toxicities during irinotecan therapy. This study was conducted to determine the maximum tolerated dose (MTD) of irinotecan chemotherapy according to the UGT1A1 genotype in previously treated lung cancer patients with the UGT1A1*28 or UGT1A1*6 polymorphism. Methods The eligibility criteria were as follows: lung cancer patients that had previously been treated with anticancer agents other than irinotecan, possessed the UGT1A1*28 or UGT1A1*6 polymorphism (group A included *28/*28, *6/*6, and *28/*6, and group B included *28/− and *6/−), were aged ≤75 years old, had a performance score of 0–1, and exhibited adequate bone marrow function. The patients were scheduled to receive irinotecan on days 1, 8, 15, 22, 29, and 36. Results Four patients were enrolled in this trial. Two patients were determined to be ineligible. The remaining two patients, who belonged to group B, received an initial irinotecan dose of 60 mg/m2, but did not complete the planned treatment because of diarrhea and leukopenia. Thus, in group B patients, 60 mg/m2 was considered to be the MTD of irinotecan. The study was terminated in group A because of poor case recruitment. Conclusions The MTD of irinotecan for previously treated lung cancer patients that are heterozygous for the UGT1A1*28 or UGT1A1*6 gene polymorphism is 60 mg/m2.
Collapse
Affiliation(s)
- Minoru Fukuda
- Clinical Oncology Center, Nagasaki University Hospital, Nagasaki, Japan
| | - Midori Shimada
- Division of Respiratory Diseases, Department of Internal Medicine, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan
| | - Takeshi Kitazaki
- Division of Respiratory Diseases, Department of Internal Medicine, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan
| | - Seiji Nagashima
- Department of Medicine, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan
| | - Kohji Hashiguchi
- Division of Respiratory Diseases, Department of Internal Medicine, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan
| | - Noriyuki Ebi
- Department of Respiratory Oncology Medicine, Iizuka Hospital, Fukuoka, Japan
| | - Koichi Takayama
- Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Yoichi Nakanishi
- Research Institute for Disease of the Chest, Graduate School of Medical Sciences, Kyusyu University, Fukuoka, Japan
| | - Hiroshi Semba
- Department of Respiratory Medicine, Kumamoto Regional Medical Center, Kumamoto, Japan
| | - Taishi Harada
- Research Institute for Disease of the Chest, Graduate School of Medical Sciences, Kyusyu University, Fukuoka, Japan
| | - Takashi Seto
- Department of Thoracic Oncology, National Kyusyu Cancer Center, Fukuoka, Japan
| | - Isamu Okamoto
- Research Institute for Disease of the Chest, Graduate School of Medical Sciences, Kyusyu University, Fukuoka, Japan
| | - Yukito Ichinose
- Clinical Research Institute, National Kyusyu Cancer Center, Fukuoka, Japan
| | - Kenji Sugio
- Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Oita, Japan.,Lung Oncology Group in Kyusyu, Fukuoka, Japan
| |
Collapse
|
30
|
Yamaguchi M, Edagawa M, Suzuki Y, Toyozawa R, Hirai F, Nosaki K, Seto T, Takenoyama M, Ichinose Y. Pulmonary Resection for Synchronous M1b-cStage IV Non-Small Cell Lung Cancer Patients. Ann Thorac Surg 2016; 103:1594-1599. [PMID: 27863731 DOI: 10.1016/j.athoracsur.2016.08.098] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/30/2016] [Revised: 08/12/2016] [Accepted: 08/22/2016] [Indexed: 10/20/2022]
Abstract
BACKGROUND We wanted to assess the efficacy of curative intent pulmonary resection for non-small cell lung cancer (NSCLC) patients with synchronous M1b-distant metastases in a single organ or lesion. METHODS Between 1995 and 2015, 23 consecutive synchronous M1b-cStage IV NSCLC patients who underwent any treatment for metastases and curative intent pulmonary resection were retrospectively analyzed. RESULTS Sixteen patients were men and 7 were women, with a median age of 56 years (range: 41 to 76 years). There were 17 adenocarcinoma, 4 large-cell carcinoma, 1 large-cell neuroendocrine cancer, and 1 carcinosarcoma. Thirteen patients had no lymph node metastasis. Fourteen patients received preoperative chemotherapy, and 10 received postoperative chemotherapy. The metastatic sites were the brain in 13 patients; bone in 3 patients; adrenal glands and extrathoracic lymph nodes in 2 patients each; and the liver, small intestine, and subcutaneous tissue in 1 patient each. Nineteen patients underwent lobectomy, and the other 4 patients underwent pneumonectomy. Seventeen patients experienced recurrence as follows: local recurrence in 3 patients, distant recurrence in 13 patients, and both in 1 patient. The 5-year progression-free survival rates in the 23 patients was14.5% (95% confidence interval: 0% to 30.6%), and the 5-year overall survival rate was 41.7% (95% confidence interval: 19.6% to 63.8%). CONCLUSIONS Some M1b-cStage IV NSCLC patients achieved longer survival than others with the same stage disease by using local treatment for distant metastases and curative intent pulmonary resection. Oligometastatic patients might have been inadvertently included in the present cohort. However, at present, the optimum method for patient selection remains unclear.
Collapse
Affiliation(s)
- Masafumi Yamaguchi
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan.
| | - Makoto Edagawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | - Yuzo Suzuki
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | - Ryo Toyozawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | - Fumihiko Hirai
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | - Kaname Nosaki
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | - Takashi Seto
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | | | - Yukito Ichinose
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| |
Collapse
|
31
|
Toyokawa G, Seto T, Takenoyama M, Ichinose Y. W'ALK' Into the Next Stage. Clin Lung Cancer 2016; 18:122-126. [PMID: 27865624 DOI: 10.1016/j.cllc.2016.10.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2016] [Revised: 10/05/2016] [Accepted: 10/12/2016] [Indexed: 01/05/2023]
Abstract
In 2007, the rearrangement of anaplastic lymphoma kinase (ALK) was identified to be associated with the pathogenesis of a subset of patients with non-small-cell lung cancer (NSCLC). Surprisingly, approximately 4 years after the discovery of ALK rearrangement in lung cancer, the first-in-class ALK inhibitor (ALKi), crizotinib, was approved for metastatic ALK-rearranged NSCLC by the US Food and Drug Administration. Subsequently, next-generation ALKis, such as alectinib and ceritinib, have been developed, and some of them have been applied in the clinical setting. Furthermore, various resistance mechanisms against ALKis have been gradually elucidated, and treatment strategies according to such resistance have been proposed. In addition, novel ALKis exhibit good antitumor efficacy for brain metastases. Thus, we now know much about ALK-rearranged NSCLC; however, is it enough? Several concerns, such as the optimal sequence of ALKis, significance of antiangiogenic therapy, immune checkpoint therapy, and cytotoxic chemotherapy in ALK-rearranged NSCLC, should be clearly addressed, which would lead to the establishment of optimal treatment strategies and a more prolonged survival in patients with ALK rearrangement. Thus, we should w'ALK' into the next stage.
Collapse
Affiliation(s)
- Gouji Toyokawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
| | - Takashi Seto
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | | | - Yukito Ichinose
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| |
Collapse
|
32
|
Kogure Y, Saka H, Takiguchi Y, Atagi S, Kurata T, Ebi N, Inoue A, Kubota K, Takenoyama M, Seto T, Kada A, Yamanaka T, Ando M, Yamamoto N, Gemma A, Ichinose Y. Carboplatin (Cb) plus nab-paclitaxel (PTX) versus docetaxel (D) for elderly squamous (Sq) non-small cell lung cancer (NSCLC) (CAPITAL study). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.99] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Nishio M, Mok T, Nakagawa K, Yamamoto N, Shi YK, Zhang L, Lu S, Soo R, Yang J, Morita S, Sugawara S, Nokihara H, Takahashi T, Goto K, Chang J, Maemondo M, Ichinose Y, Cheng Y, Lim WT, Tamura T. EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel in patients with non-small-cell lung cancer who had received a platinum-based treatment. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.18] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Abstract
Anaplastic lymphoma kinase (ALK) has been identified to exert a potent transforming activity through its rearrangement in non-small cell lung cancer (NSCLC), and patients (pts) with ALK rearrangement can be treated more successfully with ALK inhibitors, such as crizotinib, alectinib, and ceritinib, than with chemotherapy. Despite the excellent efficacy of ALK inhibitors, resistance to these drugs is inevitably encountered in most ALK-rearranged pts. Cases of resistance are subtyped into three groups, i.e., systemic, oligo, and central nervous system (CNS) types, with the CNS being used to be considered a sanctuary. With regard to the management of CNS lesions in pts with ALK+ NSCLC, a growing body of evidence has gradually demonstrated the intracranial (IC) efficacy of ALK inhibitor (ALKi) in ALK+ NSCLC pts with brain metastases (BMs). Although the efficacy of crizotinib for the CNS lesions remains controversial, a recent retrospective investigation of ALK+ pts with BM enrolled in PROFILE 1005 and PROFILE 1007 demonstrated that crizotinib is associated with a high disease control rate for BM. However, BM comprises the most common site of progressive disease in pts with or without baseline BMs, which is a serious problem for crizotinib. Furthermore, alectinib can be used to achieve strong and long-lasting inhibitory effects on BM. In addition to alectinib, the IC efficacy of other next-generation ALK inhibitors, such as ceritinib, AP26113 and PF-06463922, has been demonstrated. In this article, we review the latest evidence regarding the BM and IC efficacy of ALK inhibitors in pts with ALK+ NSCLC.
Collapse
Affiliation(s)
- Gouji Toyokawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan.
| | - Takashi Seto
- Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan
| | - Mitsuhiro Takenoyama
- Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan
| | - Yukito Ichinose
- Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan
| |
Collapse
|
35
|
Wang Y, Koh K, Ichinose Y, Yasumura M, Ohtsuka T, Takiyama Y. A de novo mutation in the NALCN gene in an adult patient with cerebellar ataxia associated with intellectual disability and arthrogryposis. Clin Genet 2016; 90:556-557. [PMID: 27633718 DOI: 10.1111/cge.12851] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2016] [Revised: 08/20/2016] [Accepted: 08/22/2016] [Indexed: 12/30/2022]
Affiliation(s)
- Y Wang
- Department of Neurology, University of Yamanashi, Yamanashi 409-3898, Japan
| | - K Koh
- Department of Neurology, University of Yamanashi, Yamanashi 409-3898, Japan
| | - Y Ichinose
- Department of Neurology, University of Yamanashi, Yamanashi 409-3898, Japan
| | - M Yasumura
- Department of Biochemistry, Graduate School of Medical Sciences, University of Yamanashi, Yamanashi 409-3898, Japan
| | - T Ohtsuka
- Department of Biochemistry, Graduate School of Medical Sciences, University of Yamanashi, Yamanashi 409-3898, Japan
| | - Y Takiyama
- Department of Neurology, University of Yamanashi, Yamanashi 409-3898, Japan
| |
Collapse
|
36
|
Takenoyama M, Ichinose Y. [Thorax/Lung and Mediastinum, Pleura: Cancer T Factor in Lung Adenocarcinoma]. Gan To Kagaku Ryoho 2016; 43:953-954. [PMID: 27996224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
|
37
|
Koh Y, Kawaguchi T, Watanabe M, Isa SI, Ando M, Tamiya A, Kubo A, Saka H, Takeo S, Adachi H, Tagawa T, Kakegawa S, Yamashita M, Kataoka K, Ichinose Y, Takeuchi Y, Sakamoto K, Matsumura A. Abstract 1376: Ultra-sensitive picodroplet digital PCR assay for multiplex genotyping of mutations in epidermal growth factor receptor (EGFR) in non-small cell lung cancer patients. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-1376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: The epidermal growth factor receptor (EGFR) mutations have been used as a reliable predictor of response to EGFR tyrosine kinase inhibitor (TKI) treatment. Two common EGFR mutations (L858R, and exon19 deletion) and EGFR T790M mutation are clinically important for decision-making in clinical practice. Picodroplet digital PCR (ddPCR) has recently emerged as an accurate and ultra-sensitive method for tumor genotyping and have a great advantage over conventional mutation detection methods. We have previously reported far more frequent incidence of pretreatment EGFR T790M mutation than previous reports utilizing ddPCR method. Here, we developed a multiplex ddPCR assay to detect three clinically relevant EGFR mutations in one reaction.
METHODS: Positive and negative control plasmids for the EGFR mutation assay were prepared by cloning DNA fragments containing wild-type or mutant EGFR. Genomic DNAs from lung cancer cell lines H1975, PC-9/ZD, A549 and wild-type human genomic DNA were digested with CviQ1, and then were used to quantitatively assess each EGFR mutant sequence in the multiplex assay panels. We then evaluated the utility of multiplex ddPCR to detect the three clinically relevant mutations in EGFR from FFPE samples of patients with non-small cell lung cancer. 45 FFPE samples were also genotyped for EGFR mutations by conventional qPCR-based methods for validation. The concordance between duplex and multiplex ddPCR assay was also evaluated.
RESULTS: Serial dilutions experiments using genomic DNA harboring EGFR mutations revealed a linear performance with an analytical sensitivity of approximately 0.01% for each mutation. All of the 33 EGFR-activating mutations detected in FFPE samples by conventional qPCR-based method were also detected by multiplex ddPCR assay. Owing to its ultra-high sensitivity, additional T790M mutation at ultra-low allele frequency (<0.1%) was also detected in the same reaction. The regression analysis between duplex and multiplex assay demonstrated a correlation coefficient (R2) of 0.9986 for L858R, 0.9844 for exon19 deletion, and 0.9959 for T790M, respectively.
CONCLUSIONS: Using ddPCR technology, we established multiplex and ultra-sensitive genotyping platform for three clinically relevant EGFR mutations. Results of a proof-of-principle study using clinical samples indicated that the clinical utility of multiplex ddPCR assay to screen for multiple EGFR-activating mutations concurrently with low-frequency T790M mutation.
Citation Format: Yasuhiro Koh, Tomoya Kawaguchi, Masaru Watanabe, Shun-ichi Isa, Masahiko Ando, Akihiro Tamiya, Akihito Kubo, Hideo Saka, Sadanori Takeo, Hirofumi Adachi, Tsutomu Tagawa, Seiichi Kakegawa, Motohiro Yamashita, Kazuhiko Kataoka, Yukito Ichinose, Yukiyasu Takeuchi, Kazuhiro Sakamoto, Akihide Matsumura. Ultra-sensitive picodroplet digital PCR assay for multiplex genotyping of mutations in epidermal growth factor receptor (EGFR) in non-small cell lung cancer patients. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1376.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Akihito Kubo
- 6Aichi Medical University School of Medicine, Aichi, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Nishiyama N, Taguchi K, Yokoyama T, Ichinose Y, Kage M. Morphometric and cytomorphologic characterization of EGFR-mutated cancer cells-comparison between cultured lung cancer cell lines and lung adenocarcinoma clinical samples. Diagn Cytopathol 2016; 44:717-24. [PMID: 27279015 DOI: 10.1002/dc.23514] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2015] [Revised: 05/09/2016] [Accepted: 05/23/2016] [Indexed: 11/10/2022]
Abstract
BACKGROUND Recently molecular targeting therapies such as inhibition of enzyme activities associated with gene mutations responsible for lung carcinogenesis have been demonstrating promising outcomes, increasing the importance of gene analysis using clinical samples. Cytomorphologic findings with predictive value toward specific gene mutation such as EGFR mutation could be a useful tool to select appropriate gene analyses using limited clinical samples. METHODS Morphometrical and cytomorphological evaluations were performed in 7 cultured lung cancer cell lines and 51 lung adenocarcinoma clinical samples to identify specific cytomorphologic characterization of EGFR-mutated cancer cells compared to the wild type. RESULTS Morphometry demonstrated that the EGFR mutated cell lines had significantly smaller nuclear area and perimeter and more circular nuclei compared to the wild type. In contrast, EGFR-mutated clinical samples had significantly greater nuclear area and perimeter compared to the wild type EGFR samples. There were no clear differences in cytomorphologic parameters assessing nuclear atypicality between EGFR mutated cells and wild type EGFR cells in either cultured cell lines or clinical samples. CONCLUSION Although our study suggested that EGFR mutation may have specific effects on nuclear morphology, no consistent characteristics of EGFR-mutated cells were identified in the clinical samples, probably due to various factors such as different pathologic stages and various incidences of lepidic growth. Further assessment of morphological characterization of EGFR-mutated cells in lung adenocarcinoma is warranted, increasing the number of samples and considering the effects of polyploidy, other gene mutations, pathology stage and tumor subtypes such as lepidic growth. Diagn. Cytopathol. 2016;44:717-724. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Naoko Nishiyama
- Department of Pathology, Kumamoto University Hospital, Kumamoto, Japan.,Department of Pathology, Clinical Division National Kyusyu Cancer Center, Fukuoka, Japan
| | - Kenichi Taguchi
- Department of Pathology, Clinical Division National Kyusyu Cancer Center, Fukuoka, Japan
| | - Toshihiro Yokoyama
- Department of Pathology, Kurume University Medical Center, Kurume, Fukuoka, Japan
| | - Yukito Ichinose
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | - Masayoshi Kage
- Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Fukuoka, Japan
| |
Collapse
|
39
|
Fukuda M, Suetsugu T, Shimada M, Kitazaki T, Hashiguchi K, Kishimoto J, Harada T, Seto T, Ebi N, Takayama K, Sugio K, Semba H, Nakanishi Y, Ichinose Y. Prospective study of the UGT1A1*27 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B). Thorac Cancer 2016; 7:467-72. [PMID: 27385990 PMCID: PMC4930967 DOI: 10.1111/1759-7714.12360] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2016] [Accepted: 04/05/2016] [Indexed: 11/27/2022] Open
Abstract
Background Uridine 5′‐diphospho‐glucuronosyltransferase 1A1 (UGT1A1*27) is known to impair the effect of UGT in basic research; however, little clinical investigation has been conducted. To evaluate the effect of the UGT1A1*27 polymorphism in irinotecan therapy, we conducted a prospective study. Methods Eligibility criteria included: lung cancer patients; scheduled irinotecan therapy doses of single ≥ 80, combination ≥ 50, radiation with single ≥ 50, or radiation with combination ≥ 40 mg/m2; age ≥ 20; and Eastern Cooperative Oncology Group performance score (PS) 0–2. Patients were examined for UGT1A1*28 and *6 polymorphisms and received irinotecan. When the UGT1A1*28 polymorphism was detected, a search for UGT1A1*27 was conducted. Fifty patients were enrolled, with 48 patients determined eligible. Results UGT1A1 polymorphisms *28/*28, *6/*6, *28/*6, *28/−, *6/−, −/− observed 0 (0%), 1 (2%), 1 (2%), 7 (15%), 17 (35%) and 22 (46%), respectively. UGT1A1*27 were examined in nine patients including one ineligible patient; however, no polymorphisms were found. The study ceased after interim analysis. In an evaluation of the side effects of irinotecan, patients with UGT1A1*28 and UGT1A1*6 polymorphisms had a higher tendency to experience febrile neutropenia than wild type (25% and 32% vs. 14%). Incidences of grade 3/4 leukopenia and neutropenia were significantly higher in patients with UGT1A1*28 polymorphisms compared with wild type (75% vs. 32%, P = 0.049; 75% vs. 36%, P = 0.039, respectively). Conclusion Our prospective study did not locate the UGT1A1*27 polymorphism, suggesting that UGT1A1*27 does not significantly predict severe irinotecan toxicity in cancer patients.
Collapse
Affiliation(s)
- Minoru Fukuda
- Clinical Oncology Center, Nagasaki University Hospital Nagasaki Japan
| | - Takayuki Suetsugu
- Department of Respiratory Medicine Sendai Medical Association Hospital Kagoshima Japan
| | - Midori Shimada
- Division of Respiratory Diseases, Department of Internal Medicine Japanese Red Cross Nagasaki Genbaku Hospital Nagasaki Japan
| | - Takeshi Kitazaki
- Division of Respiratory Diseases, Department of Internal Medicine Japanese Red Cross Nagasaki Genbaku Hospital Nagasaki Japan
| | - Kohji Hashiguchi
- Division of Respiratory Diseases, Department of Internal Medicine Japanese Red Cross Nagasaki Genbaku Hospital Nagasaki Japan
| | - Junji Kishimoto
- Department of Research and Development of Next Generation Medicine Kyusyu University Fukuoka Japan
| | - Taishi Harada
- Graduate School of Medical Sciences, Research Institute for Disease of the Chest Kyusyu University Fukuoka Japan
| | - Takashi Seto
- Department of Thoracic Oncology National Kyusyu Cancer Center Fukuoka Japan
| | - Noriyuki Ebi
- Department of Respiratory Oncology Medicine Iizuka Hospital Fukuoka Japan
| | - Koichi Takayama
- Department of Pulmonary Medicine Kyoto Prefectual University of Medicine Kyoto Japan
| | - Kenji Sugio
- Department of Thoracic and Breast Surgery Oita University Faculty of Medicine Oita Japan
| | - Hiroshi Semba
- Department of Respiratory Medicine Kumamoto Regional Medical Center Kumamoto Japan
| | - Yoichi Nakanishi
- Graduate School of Medical Sciences, Research Institute for Disease of the Chest Kyusyu University Fukuoka Japan
| | - Yukito Ichinose
- Clinical Research Institute, National Kyusyu Cancer Center Fukuoka Japan
| |
Collapse
|
40
|
Kawaguchi T, Koh Y, Ando M, Ito N, Takeo S, Adachi H, Tagawa T, Kakegawa S, Yamashita M, Kataoka K, Ichinose Y, Takeuchi Y, Serizawa M, Tamiya A, Shimizu S, Yoshimoto N, Kubo A, Isa SI, Saka H, Matsumura A. Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study. J Clin Oncol 2016; 34:2247-57. [PMID: 27161973 DOI: 10.1200/jco.2015.64.2322] [Citation(s) in RCA: 82] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
PURPOSE Oncogenic driver mutations are critical for lung cancer development and serve as therapeutic targets. However, their associations with environmental factors are not fully understood. We aimed to elucidate the relationship between tumor developmental biology and exposure to environmental factors. PATIENTS AND METHODS This was a prospective, multicenter, molecular epidemiology study. Eligible patients were those with newly diagnosed stages I to IIIB non-small-cell lung cancer (NSCLC) who underwent surgery. The tumors were examined for somatic mutations in 72 cancer-associated genes by targeted deep sequencing, estrogen receptor β (ERβ) expression using immunohistochemical staining, and infection with any of 37 types of human papillomavirus (HPV) using a polymerase chain reaction-based microarray system. Detailed information on patient demographics and environmental factors was obtained from a comprehensive questionnaire. RESULTS From July 2012 to December 2013, 957 patients were enrolled, and molecular analyses were performed on 876 samples (from 441 ever- and 435 never-smokers). Oncogenic driver mutations in P53 and KRAS increased proportionally with smoking status, whereas mutations in EGFR and SMAD4 decreased. KRAS mutations in smokers and SMAD4 mutations were observed more frequently in proportion to body mass index. TP53 and NFE2L2 mutations were observed more frequently in advanced NSCLC stages. As for never-smokers, no environmental factors were significantly associated with mutational changes. EGFR mutations and TP53 mutations were observed more frequently in women and in men, respectively. Mutations in these two genes were also potentially associated with ERβ expression. Only three patients (0.3%) were HPV positive. CONCLUSION The mutational spectrum is associated with smoking, body mass index, and other environmental factors, as well as with ERβ expression. Little association was observed between HPV and NSCLC.
Collapse
Affiliation(s)
- Tomoya Kawaguchi
- Tomoya Kawaguchi, Akihiro Tamiya, Shigeki Shimizu, Shun-ichi Isa, and Akihide Matsumura, National Hospital Organization Kinki-chuo Chest Medical Center; Tomoya Kawaguchi and Naoki Yoshimoto, Osaka City University, Osaka; Yasuhiro Koh, Seiichi Kakegawa, Masakuni Serizawa, Akihito Kubo, and Hideo Saka, National Hospital Organization Nagoya Medical Center; Masahiko Ando, Nagoya University, Nagoya; Yasuhiro Koh, Wakayama Medical University, Wakayama; Yasuhiro Koh and Masakuni Serizawa, Shizuoka Cancer Center Research Institute, Shizuoka; Norimasa Ito, National Hospital Organization Matsue Medical Center, Matsue; Sadanori Takeo, National Hospital Organization Kyushu Medical Center; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hirofumi Adachi, National Hospital Organization Hokkaido Cancer Center, Hokkaido; Tsutomu Tagawa, National Hospital Organization Nagasaki Medical Center, Omura; Seiichi Kakegawa, National Hospital Organization Nishigunma National Hospital, Shibukawa; Motohiro Yamashita, National Hospital Organization Shikoku Cancer Center, Matsuyama; Kazuhiko Kataoka, National Hospital Organization Iwakuni Clinical Center, Iwakuni; Yukiyasu Takeuchi, National Hospital Organization Toneyama National Hospital, Toyonaka; Shigeki Shimizu, Hyogo Medical Collage, Hyogo; and Akihito Kubo, Aichi Medical University School of Medicine, Aichi, Japan.
| | - Yasuhiro Koh
- Tomoya Kawaguchi, Akihiro Tamiya, Shigeki Shimizu, Shun-ichi Isa, and Akihide Matsumura, National Hospital Organization Kinki-chuo Chest Medical Center; Tomoya Kawaguchi and Naoki Yoshimoto, Osaka City University, Osaka; Yasuhiro Koh, Seiichi Kakegawa, Masakuni Serizawa, Akihito Kubo, and Hideo Saka, National Hospital Organization Nagoya Medical Center; Masahiko Ando, Nagoya University, Nagoya; Yasuhiro Koh, Wakayama Medical University, Wakayama; Yasuhiro Koh and Masakuni Serizawa, Shizuoka Cancer Center Research Institute, Shizuoka; Norimasa Ito, National Hospital Organization Matsue Medical Center, Matsue; Sadanori Takeo, National Hospital Organization Kyushu Medical Center; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hirofumi Adachi, National Hospital Organization Hokkaido Cancer Center, Hokkaido; Tsutomu Tagawa, National Hospital Organization Nagasaki Medical Center, Omura; Seiichi Kakegawa, National Hospital Organization Nishigunma National Hospital, Shibukawa; Motohiro Yamashita, National Hospital Organization Shikoku Cancer Center, Matsuyama; Kazuhiko Kataoka, National Hospital Organization Iwakuni Clinical Center, Iwakuni; Yukiyasu Takeuchi, National Hospital Organization Toneyama National Hospital, Toyonaka; Shigeki Shimizu, Hyogo Medical Collage, Hyogo; and Akihito Kubo, Aichi Medical University School of Medicine, Aichi, Japan
| | - Masahiko Ando
- Tomoya Kawaguchi, Akihiro Tamiya, Shigeki Shimizu, Shun-ichi Isa, and Akihide Matsumura, National Hospital Organization Kinki-chuo Chest Medical Center; Tomoya Kawaguchi and Naoki Yoshimoto, Osaka City University, Osaka; Yasuhiro Koh, Seiichi Kakegawa, Masakuni Serizawa, Akihito Kubo, and Hideo Saka, National Hospital Organization Nagoya Medical Center; Masahiko Ando, Nagoya University, Nagoya; Yasuhiro Koh, Wakayama Medical University, Wakayama; Yasuhiro Koh and Masakuni Serizawa, Shizuoka Cancer Center Research Institute, Shizuoka; Norimasa Ito, National Hospital Organization Matsue Medical Center, Matsue; Sadanori Takeo, National Hospital Organization Kyushu Medical Center; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hirofumi Adachi, National Hospital Organization Hokkaido Cancer Center, Hokkaido; Tsutomu Tagawa, National Hospital Organization Nagasaki Medical Center, Omura; Seiichi Kakegawa, National Hospital Organization Nishigunma National Hospital, Shibukawa; Motohiro Yamashita, National Hospital Organization Shikoku Cancer Center, Matsuyama; Kazuhiko Kataoka, National Hospital Organization Iwakuni Clinical Center, Iwakuni; Yukiyasu Takeuchi, National Hospital Organization Toneyama National Hospital, Toyonaka; Shigeki Shimizu, Hyogo Medical Collage, Hyogo; and Akihito Kubo, Aichi Medical University School of Medicine, Aichi, Japan
| | - Norimasa Ito
- Tomoya Kawaguchi, Akihiro Tamiya, Shigeki Shimizu, Shun-ichi Isa, and Akihide Matsumura, National Hospital Organization Kinki-chuo Chest Medical Center; Tomoya Kawaguchi and Naoki Yoshimoto, Osaka City University, Osaka; Yasuhiro Koh, Seiichi Kakegawa, Masakuni Serizawa, Akihito Kubo, and Hideo Saka, National Hospital Organization Nagoya Medical Center; Masahiko Ando, Nagoya University, Nagoya; Yasuhiro Koh, Wakayama Medical University, Wakayama; Yasuhiro Koh and Masakuni Serizawa, Shizuoka Cancer Center Research Institute, Shizuoka; Norimasa Ito, National Hospital Organization Matsue Medical Center, Matsue; Sadanori Takeo, National Hospital Organization Kyushu Medical Center; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hirofumi Adachi, National Hospital Organization Hokkaido Cancer Center, Hokkaido; Tsutomu Tagawa, National Hospital Organization Nagasaki Medical Center, Omura; Seiichi Kakegawa, National Hospital Organization Nishigunma National Hospital, Shibukawa; Motohiro Yamashita, National Hospital Organization Shikoku Cancer Center, Matsuyama; Kazuhiko Kataoka, National Hospital Organization Iwakuni Clinical Center, Iwakuni; Yukiyasu Takeuchi, National Hospital Organization Toneyama National Hospital, Toyonaka; Shigeki Shimizu, Hyogo Medical Collage, Hyogo; and Akihito Kubo, Aichi Medical University School of Medicine, Aichi, Japan
| | - Sadanori Takeo
- Tomoya Kawaguchi, Akihiro Tamiya, Shigeki Shimizu, Shun-ichi Isa, and Akihide Matsumura, National Hospital Organization Kinki-chuo Chest Medical Center; Tomoya Kawaguchi and Naoki Yoshimoto, Osaka City University, Osaka; Yasuhiro Koh, Seiichi Kakegawa, Masakuni Serizawa, Akihito Kubo, and Hideo Saka, National Hospital Organization Nagoya Medical Center; Masahiko Ando, Nagoya University, Nagoya; Yasuhiro Koh, Wakayama Medical University, Wakayama; Yasuhiro Koh and Masakuni Serizawa, Shizuoka Cancer Center Research Institute, Shizuoka; Norimasa Ito, National Hospital Organization Matsue Medical Center, Matsue; Sadanori Takeo, National Hospital Organization Kyushu Medical Center; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hirofumi Adachi, National Hospital Organization Hokkaido Cancer Center, Hokkaido; Tsutomu Tagawa, National Hospital Organization Nagasaki Medical Center, Omura; Seiichi Kakegawa, National Hospital Organization Nishigunma National Hospital, Shibukawa; Motohiro Yamashita, National Hospital Organization Shikoku Cancer Center, Matsuyama; Kazuhiko Kataoka, National Hospital Organization Iwakuni Clinical Center, Iwakuni; Yukiyasu Takeuchi, National Hospital Organization Toneyama National Hospital, Toyonaka; Shigeki Shimizu, Hyogo Medical Collage, Hyogo; and Akihito Kubo, Aichi Medical University School of Medicine, Aichi, Japan
| | - Hirofumi Adachi
- Tomoya Kawaguchi, Akihiro Tamiya, Shigeki Shimizu, Shun-ichi Isa, and Akihide Matsumura, National Hospital Organization Kinki-chuo Chest Medical Center; Tomoya Kawaguchi and Naoki Yoshimoto, Osaka City University, Osaka; Yasuhiro Koh, Seiichi Kakegawa, Masakuni Serizawa, Akihito Kubo, and Hideo Saka, National Hospital Organization Nagoya Medical Center; Masahiko Ando, Nagoya University, Nagoya; Yasuhiro Koh, Wakayama Medical University, Wakayama; Yasuhiro Koh and Masakuni Serizawa, Shizuoka Cancer Center Research Institute, Shizuoka; Norimasa Ito, National Hospital Organization Matsue Medical Center, Matsue; Sadanori Takeo, National Hospital Organization Kyushu Medical Center; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hirofumi Adachi, National Hospital Organization Hokkaido Cancer Center, Hokkaido; Tsutomu Tagawa, National Hospital Organization Nagasaki Medical Center, Omura; Seiichi Kakegawa, National Hospital Organization Nishigunma National Hospital, Shibukawa; Motohiro Yamashita, National Hospital Organization Shikoku Cancer Center, Matsuyama; Kazuhiko Kataoka, National Hospital Organization Iwakuni Clinical Center, Iwakuni; Yukiyasu Takeuchi, National Hospital Organization Toneyama National Hospital, Toyonaka; Shigeki Shimizu, Hyogo Medical Collage, Hyogo; and Akihito Kubo, Aichi Medical University School of Medicine, Aichi, Japan
| | - Tsutomu Tagawa
- Tomoya Kawaguchi, Akihiro Tamiya, Shigeki Shimizu, Shun-ichi Isa, and Akihide Matsumura, National Hospital Organization Kinki-chuo Chest Medical Center; Tomoya Kawaguchi and Naoki Yoshimoto, Osaka City University, Osaka; Yasuhiro Koh, Seiichi Kakegawa, Masakuni Serizawa, Akihito Kubo, and Hideo Saka, National Hospital Organization Nagoya Medical Center; Masahiko Ando, Nagoya University, Nagoya; Yasuhiro Koh, Wakayama Medical University, Wakayama; Yasuhiro Koh and Masakuni Serizawa, Shizuoka Cancer Center Research Institute, Shizuoka; Norimasa Ito, National Hospital Organization Matsue Medical Center, Matsue; Sadanori Takeo, National Hospital Organization Kyushu Medical Center; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hirofumi Adachi, National Hospital Organization Hokkaido Cancer Center, Hokkaido; Tsutomu Tagawa, National Hospital Organization Nagasaki Medical Center, Omura; Seiichi Kakegawa, National Hospital Organization Nishigunma National Hospital, Shibukawa; Motohiro Yamashita, National Hospital Organization Shikoku Cancer Center, Matsuyama; Kazuhiko Kataoka, National Hospital Organization Iwakuni Clinical Center, Iwakuni; Yukiyasu Takeuchi, National Hospital Organization Toneyama National Hospital, Toyonaka; Shigeki Shimizu, Hyogo Medical Collage, Hyogo; and Akihito Kubo, Aichi Medical University School of Medicine, Aichi, Japan
| | - Seiichi Kakegawa
- Tomoya Kawaguchi, Akihiro Tamiya, Shigeki Shimizu, Shun-ichi Isa, and Akihide Matsumura, National Hospital Organization Kinki-chuo Chest Medical Center; Tomoya Kawaguchi and Naoki Yoshimoto, Osaka City University, Osaka; Yasuhiro Koh, Seiichi Kakegawa, Masakuni Serizawa, Akihito Kubo, and Hideo Saka, National Hospital Organization Nagoya Medical Center; Masahiko Ando, Nagoya University, Nagoya; Yasuhiro Koh, Wakayama Medical University, Wakayama; Yasuhiro Koh and Masakuni Serizawa, Shizuoka Cancer Center Research Institute, Shizuoka; Norimasa Ito, National Hospital Organization Matsue Medical Center, Matsue; Sadanori Takeo, National Hospital Organization Kyushu Medical Center; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hirofumi Adachi, National Hospital Organization Hokkaido Cancer Center, Hokkaido; Tsutomu Tagawa, National Hospital Organization Nagasaki Medical Center, Omura; Seiichi Kakegawa, National Hospital Organization Nishigunma National Hospital, Shibukawa; Motohiro Yamashita, National Hospital Organization Shikoku Cancer Center, Matsuyama; Kazuhiko Kataoka, National Hospital Organization Iwakuni Clinical Center, Iwakuni; Yukiyasu Takeuchi, National Hospital Organization Toneyama National Hospital, Toyonaka; Shigeki Shimizu, Hyogo Medical Collage, Hyogo; and Akihito Kubo, Aichi Medical University School of Medicine, Aichi, Japan
| | - Motohiro Yamashita
- Tomoya Kawaguchi, Akihiro Tamiya, Shigeki Shimizu, Shun-ichi Isa, and Akihide Matsumura, National Hospital Organization Kinki-chuo Chest Medical Center; Tomoya Kawaguchi and Naoki Yoshimoto, Osaka City University, Osaka; Yasuhiro Koh, Seiichi Kakegawa, Masakuni Serizawa, Akihito Kubo, and Hideo Saka, National Hospital Organization Nagoya Medical Center; Masahiko Ando, Nagoya University, Nagoya; Yasuhiro Koh, Wakayama Medical University, Wakayama; Yasuhiro Koh and Masakuni Serizawa, Shizuoka Cancer Center Research Institute, Shizuoka; Norimasa Ito, National Hospital Organization Matsue Medical Center, Matsue; Sadanori Takeo, National Hospital Organization Kyushu Medical Center; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hirofumi Adachi, National Hospital Organization Hokkaido Cancer Center, Hokkaido; Tsutomu Tagawa, National Hospital Organization Nagasaki Medical Center, Omura; Seiichi Kakegawa, National Hospital Organization Nishigunma National Hospital, Shibukawa; Motohiro Yamashita, National Hospital Organization Shikoku Cancer Center, Matsuyama; Kazuhiko Kataoka, National Hospital Organization Iwakuni Clinical Center, Iwakuni; Yukiyasu Takeuchi, National Hospital Organization Toneyama National Hospital, Toyonaka; Shigeki Shimizu, Hyogo Medical Collage, Hyogo; and Akihito Kubo, Aichi Medical University School of Medicine, Aichi, Japan
| | - Kazuhiko Kataoka
- Tomoya Kawaguchi, Akihiro Tamiya, Shigeki Shimizu, Shun-ichi Isa, and Akihide Matsumura, National Hospital Organization Kinki-chuo Chest Medical Center; Tomoya Kawaguchi and Naoki Yoshimoto, Osaka City University, Osaka; Yasuhiro Koh, Seiichi Kakegawa, Masakuni Serizawa, Akihito Kubo, and Hideo Saka, National Hospital Organization Nagoya Medical Center; Masahiko Ando, Nagoya University, Nagoya; Yasuhiro Koh, Wakayama Medical University, Wakayama; Yasuhiro Koh and Masakuni Serizawa, Shizuoka Cancer Center Research Institute, Shizuoka; Norimasa Ito, National Hospital Organization Matsue Medical Center, Matsue; Sadanori Takeo, National Hospital Organization Kyushu Medical Center; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hirofumi Adachi, National Hospital Organization Hokkaido Cancer Center, Hokkaido; Tsutomu Tagawa, National Hospital Organization Nagasaki Medical Center, Omura; Seiichi Kakegawa, National Hospital Organization Nishigunma National Hospital, Shibukawa; Motohiro Yamashita, National Hospital Organization Shikoku Cancer Center, Matsuyama; Kazuhiko Kataoka, National Hospital Organization Iwakuni Clinical Center, Iwakuni; Yukiyasu Takeuchi, National Hospital Organization Toneyama National Hospital, Toyonaka; Shigeki Shimizu, Hyogo Medical Collage, Hyogo; and Akihito Kubo, Aichi Medical University School of Medicine, Aichi, Japan
| | - Yukito Ichinose
- Tomoya Kawaguchi, Akihiro Tamiya, Shigeki Shimizu, Shun-ichi Isa, and Akihide Matsumura, National Hospital Organization Kinki-chuo Chest Medical Center; Tomoya Kawaguchi and Naoki Yoshimoto, Osaka City University, Osaka; Yasuhiro Koh, Seiichi Kakegawa, Masakuni Serizawa, Akihito Kubo, and Hideo Saka, National Hospital Organization Nagoya Medical Center; Masahiko Ando, Nagoya University, Nagoya; Yasuhiro Koh, Wakayama Medical University, Wakayama; Yasuhiro Koh and Masakuni Serizawa, Shizuoka Cancer Center Research Institute, Shizuoka; Norimasa Ito, National Hospital Organization Matsue Medical Center, Matsue; Sadanori Takeo, National Hospital Organization Kyushu Medical Center; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hirofumi Adachi, National Hospital Organization Hokkaido Cancer Center, Hokkaido; Tsutomu Tagawa, National Hospital Organization Nagasaki Medical Center, Omura; Seiichi Kakegawa, National Hospital Organization Nishigunma National Hospital, Shibukawa; Motohiro Yamashita, National Hospital Organization Shikoku Cancer Center, Matsuyama; Kazuhiko Kataoka, National Hospital Organization Iwakuni Clinical Center, Iwakuni; Yukiyasu Takeuchi, National Hospital Organization Toneyama National Hospital, Toyonaka; Shigeki Shimizu, Hyogo Medical Collage, Hyogo; and Akihito Kubo, Aichi Medical University School of Medicine, Aichi, Japan
| | - Yukiyasu Takeuchi
- Tomoya Kawaguchi, Akihiro Tamiya, Shigeki Shimizu, Shun-ichi Isa, and Akihide Matsumura, National Hospital Organization Kinki-chuo Chest Medical Center; Tomoya Kawaguchi and Naoki Yoshimoto, Osaka City University, Osaka; Yasuhiro Koh, Seiichi Kakegawa, Masakuni Serizawa, Akihito Kubo, and Hideo Saka, National Hospital Organization Nagoya Medical Center; Masahiko Ando, Nagoya University, Nagoya; Yasuhiro Koh, Wakayama Medical University, Wakayama; Yasuhiro Koh and Masakuni Serizawa, Shizuoka Cancer Center Research Institute, Shizuoka; Norimasa Ito, National Hospital Organization Matsue Medical Center, Matsue; Sadanori Takeo, National Hospital Organization Kyushu Medical Center; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hirofumi Adachi, National Hospital Organization Hokkaido Cancer Center, Hokkaido; Tsutomu Tagawa, National Hospital Organization Nagasaki Medical Center, Omura; Seiichi Kakegawa, National Hospital Organization Nishigunma National Hospital, Shibukawa; Motohiro Yamashita, National Hospital Organization Shikoku Cancer Center, Matsuyama; Kazuhiko Kataoka, National Hospital Organization Iwakuni Clinical Center, Iwakuni; Yukiyasu Takeuchi, National Hospital Organization Toneyama National Hospital, Toyonaka; Shigeki Shimizu, Hyogo Medical Collage, Hyogo; and Akihito Kubo, Aichi Medical University School of Medicine, Aichi, Japan
| | - Masakuni Serizawa
- Tomoya Kawaguchi, Akihiro Tamiya, Shigeki Shimizu, Shun-ichi Isa, and Akihide Matsumura, National Hospital Organization Kinki-chuo Chest Medical Center; Tomoya Kawaguchi and Naoki Yoshimoto, Osaka City University, Osaka; Yasuhiro Koh, Seiichi Kakegawa, Masakuni Serizawa, Akihito Kubo, and Hideo Saka, National Hospital Organization Nagoya Medical Center; Masahiko Ando, Nagoya University, Nagoya; Yasuhiro Koh, Wakayama Medical University, Wakayama; Yasuhiro Koh and Masakuni Serizawa, Shizuoka Cancer Center Research Institute, Shizuoka; Norimasa Ito, National Hospital Organization Matsue Medical Center, Matsue; Sadanori Takeo, National Hospital Organization Kyushu Medical Center; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hirofumi Adachi, National Hospital Organization Hokkaido Cancer Center, Hokkaido; Tsutomu Tagawa, National Hospital Organization Nagasaki Medical Center, Omura; Seiichi Kakegawa, National Hospital Organization Nishigunma National Hospital, Shibukawa; Motohiro Yamashita, National Hospital Organization Shikoku Cancer Center, Matsuyama; Kazuhiko Kataoka, National Hospital Organization Iwakuni Clinical Center, Iwakuni; Yukiyasu Takeuchi, National Hospital Organization Toneyama National Hospital, Toyonaka; Shigeki Shimizu, Hyogo Medical Collage, Hyogo; and Akihito Kubo, Aichi Medical University School of Medicine, Aichi, Japan
| | - Akihiro Tamiya
- Tomoya Kawaguchi, Akihiro Tamiya, Shigeki Shimizu, Shun-ichi Isa, and Akihide Matsumura, National Hospital Organization Kinki-chuo Chest Medical Center; Tomoya Kawaguchi and Naoki Yoshimoto, Osaka City University, Osaka; Yasuhiro Koh, Seiichi Kakegawa, Masakuni Serizawa, Akihito Kubo, and Hideo Saka, National Hospital Organization Nagoya Medical Center; Masahiko Ando, Nagoya University, Nagoya; Yasuhiro Koh, Wakayama Medical University, Wakayama; Yasuhiro Koh and Masakuni Serizawa, Shizuoka Cancer Center Research Institute, Shizuoka; Norimasa Ito, National Hospital Organization Matsue Medical Center, Matsue; Sadanori Takeo, National Hospital Organization Kyushu Medical Center; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hirofumi Adachi, National Hospital Organization Hokkaido Cancer Center, Hokkaido; Tsutomu Tagawa, National Hospital Organization Nagasaki Medical Center, Omura; Seiichi Kakegawa, National Hospital Organization Nishigunma National Hospital, Shibukawa; Motohiro Yamashita, National Hospital Organization Shikoku Cancer Center, Matsuyama; Kazuhiko Kataoka, National Hospital Organization Iwakuni Clinical Center, Iwakuni; Yukiyasu Takeuchi, National Hospital Organization Toneyama National Hospital, Toyonaka; Shigeki Shimizu, Hyogo Medical Collage, Hyogo; and Akihito Kubo, Aichi Medical University School of Medicine, Aichi, Japan
| | - Shigeki Shimizu
- Tomoya Kawaguchi, Akihiro Tamiya, Shigeki Shimizu, Shun-ichi Isa, and Akihide Matsumura, National Hospital Organization Kinki-chuo Chest Medical Center; Tomoya Kawaguchi and Naoki Yoshimoto, Osaka City University, Osaka; Yasuhiro Koh, Seiichi Kakegawa, Masakuni Serizawa, Akihito Kubo, and Hideo Saka, National Hospital Organization Nagoya Medical Center; Masahiko Ando, Nagoya University, Nagoya; Yasuhiro Koh, Wakayama Medical University, Wakayama; Yasuhiro Koh and Masakuni Serizawa, Shizuoka Cancer Center Research Institute, Shizuoka; Norimasa Ito, National Hospital Organization Matsue Medical Center, Matsue; Sadanori Takeo, National Hospital Organization Kyushu Medical Center; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hirofumi Adachi, National Hospital Organization Hokkaido Cancer Center, Hokkaido; Tsutomu Tagawa, National Hospital Organization Nagasaki Medical Center, Omura; Seiichi Kakegawa, National Hospital Organization Nishigunma National Hospital, Shibukawa; Motohiro Yamashita, National Hospital Organization Shikoku Cancer Center, Matsuyama; Kazuhiko Kataoka, National Hospital Organization Iwakuni Clinical Center, Iwakuni; Yukiyasu Takeuchi, National Hospital Organization Toneyama National Hospital, Toyonaka; Shigeki Shimizu, Hyogo Medical Collage, Hyogo; and Akihito Kubo, Aichi Medical University School of Medicine, Aichi, Japan
| | - Naoki Yoshimoto
- Tomoya Kawaguchi, Akihiro Tamiya, Shigeki Shimizu, Shun-ichi Isa, and Akihide Matsumura, National Hospital Organization Kinki-chuo Chest Medical Center; Tomoya Kawaguchi and Naoki Yoshimoto, Osaka City University, Osaka; Yasuhiro Koh, Seiichi Kakegawa, Masakuni Serizawa, Akihito Kubo, and Hideo Saka, National Hospital Organization Nagoya Medical Center; Masahiko Ando, Nagoya University, Nagoya; Yasuhiro Koh, Wakayama Medical University, Wakayama; Yasuhiro Koh and Masakuni Serizawa, Shizuoka Cancer Center Research Institute, Shizuoka; Norimasa Ito, National Hospital Organization Matsue Medical Center, Matsue; Sadanori Takeo, National Hospital Organization Kyushu Medical Center; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hirofumi Adachi, National Hospital Organization Hokkaido Cancer Center, Hokkaido; Tsutomu Tagawa, National Hospital Organization Nagasaki Medical Center, Omura; Seiichi Kakegawa, National Hospital Organization Nishigunma National Hospital, Shibukawa; Motohiro Yamashita, National Hospital Organization Shikoku Cancer Center, Matsuyama; Kazuhiko Kataoka, National Hospital Organization Iwakuni Clinical Center, Iwakuni; Yukiyasu Takeuchi, National Hospital Organization Toneyama National Hospital, Toyonaka; Shigeki Shimizu, Hyogo Medical Collage, Hyogo; and Akihito Kubo, Aichi Medical University School of Medicine, Aichi, Japan
| | - Akihito Kubo
- Tomoya Kawaguchi, Akihiro Tamiya, Shigeki Shimizu, Shun-ichi Isa, and Akihide Matsumura, National Hospital Organization Kinki-chuo Chest Medical Center; Tomoya Kawaguchi and Naoki Yoshimoto, Osaka City University, Osaka; Yasuhiro Koh, Seiichi Kakegawa, Masakuni Serizawa, Akihito Kubo, and Hideo Saka, National Hospital Organization Nagoya Medical Center; Masahiko Ando, Nagoya University, Nagoya; Yasuhiro Koh, Wakayama Medical University, Wakayama; Yasuhiro Koh and Masakuni Serizawa, Shizuoka Cancer Center Research Institute, Shizuoka; Norimasa Ito, National Hospital Organization Matsue Medical Center, Matsue; Sadanori Takeo, National Hospital Organization Kyushu Medical Center; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hirofumi Adachi, National Hospital Organization Hokkaido Cancer Center, Hokkaido; Tsutomu Tagawa, National Hospital Organization Nagasaki Medical Center, Omura; Seiichi Kakegawa, National Hospital Organization Nishigunma National Hospital, Shibukawa; Motohiro Yamashita, National Hospital Organization Shikoku Cancer Center, Matsuyama; Kazuhiko Kataoka, National Hospital Organization Iwakuni Clinical Center, Iwakuni; Yukiyasu Takeuchi, National Hospital Organization Toneyama National Hospital, Toyonaka; Shigeki Shimizu, Hyogo Medical Collage, Hyogo; and Akihito Kubo, Aichi Medical University School of Medicine, Aichi, Japan
| | - Shun-Ichi Isa
- Tomoya Kawaguchi, Akihiro Tamiya, Shigeki Shimizu, Shun-ichi Isa, and Akihide Matsumura, National Hospital Organization Kinki-chuo Chest Medical Center; Tomoya Kawaguchi and Naoki Yoshimoto, Osaka City University, Osaka; Yasuhiro Koh, Seiichi Kakegawa, Masakuni Serizawa, Akihito Kubo, and Hideo Saka, National Hospital Organization Nagoya Medical Center; Masahiko Ando, Nagoya University, Nagoya; Yasuhiro Koh, Wakayama Medical University, Wakayama; Yasuhiro Koh and Masakuni Serizawa, Shizuoka Cancer Center Research Institute, Shizuoka; Norimasa Ito, National Hospital Organization Matsue Medical Center, Matsue; Sadanori Takeo, National Hospital Organization Kyushu Medical Center; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hirofumi Adachi, National Hospital Organization Hokkaido Cancer Center, Hokkaido; Tsutomu Tagawa, National Hospital Organization Nagasaki Medical Center, Omura; Seiichi Kakegawa, National Hospital Organization Nishigunma National Hospital, Shibukawa; Motohiro Yamashita, National Hospital Organization Shikoku Cancer Center, Matsuyama; Kazuhiko Kataoka, National Hospital Organization Iwakuni Clinical Center, Iwakuni; Yukiyasu Takeuchi, National Hospital Organization Toneyama National Hospital, Toyonaka; Shigeki Shimizu, Hyogo Medical Collage, Hyogo; and Akihito Kubo, Aichi Medical University School of Medicine, Aichi, Japan
| | - Hideo Saka
- Tomoya Kawaguchi, Akihiro Tamiya, Shigeki Shimizu, Shun-ichi Isa, and Akihide Matsumura, National Hospital Organization Kinki-chuo Chest Medical Center; Tomoya Kawaguchi and Naoki Yoshimoto, Osaka City University, Osaka; Yasuhiro Koh, Seiichi Kakegawa, Masakuni Serizawa, Akihito Kubo, and Hideo Saka, National Hospital Organization Nagoya Medical Center; Masahiko Ando, Nagoya University, Nagoya; Yasuhiro Koh, Wakayama Medical University, Wakayama; Yasuhiro Koh and Masakuni Serizawa, Shizuoka Cancer Center Research Institute, Shizuoka; Norimasa Ito, National Hospital Organization Matsue Medical Center, Matsue; Sadanori Takeo, National Hospital Organization Kyushu Medical Center; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hirofumi Adachi, National Hospital Organization Hokkaido Cancer Center, Hokkaido; Tsutomu Tagawa, National Hospital Organization Nagasaki Medical Center, Omura; Seiichi Kakegawa, National Hospital Organization Nishigunma National Hospital, Shibukawa; Motohiro Yamashita, National Hospital Organization Shikoku Cancer Center, Matsuyama; Kazuhiko Kataoka, National Hospital Organization Iwakuni Clinical Center, Iwakuni; Yukiyasu Takeuchi, National Hospital Organization Toneyama National Hospital, Toyonaka; Shigeki Shimizu, Hyogo Medical Collage, Hyogo; and Akihito Kubo, Aichi Medical University School of Medicine, Aichi, Japan
| | - Akihide Matsumura
- Tomoya Kawaguchi, Akihiro Tamiya, Shigeki Shimizu, Shun-ichi Isa, and Akihide Matsumura, National Hospital Organization Kinki-chuo Chest Medical Center; Tomoya Kawaguchi and Naoki Yoshimoto, Osaka City University, Osaka; Yasuhiro Koh, Seiichi Kakegawa, Masakuni Serizawa, Akihito Kubo, and Hideo Saka, National Hospital Organization Nagoya Medical Center; Masahiko Ando, Nagoya University, Nagoya; Yasuhiro Koh, Wakayama Medical University, Wakayama; Yasuhiro Koh and Masakuni Serizawa, Shizuoka Cancer Center Research Institute, Shizuoka; Norimasa Ito, National Hospital Organization Matsue Medical Center, Matsue; Sadanori Takeo, National Hospital Organization Kyushu Medical Center; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hirofumi Adachi, National Hospital Organization Hokkaido Cancer Center, Hokkaido; Tsutomu Tagawa, National Hospital Organization Nagasaki Medical Center, Omura; Seiichi Kakegawa, National Hospital Organization Nishigunma National Hospital, Shibukawa; Motohiro Yamashita, National Hospital Organization Shikoku Cancer Center, Matsuyama; Kazuhiko Kataoka, National Hospital Organization Iwakuni Clinical Center, Iwakuni; Yukiyasu Takeuchi, National Hospital Organization Toneyama National Hospital, Toyonaka; Shigeki Shimizu, Hyogo Medical Collage, Hyogo; and Akihito Kubo, Aichi Medical University School of Medicine, Aichi, Japan
| |
Collapse
|
41
|
Hirai F, Edagawa M, Shimamatsu S, Toyozawa R, Toyokawa G, Nosaki K, Yamaguchi M, Seto T, Twakenoyama M, Ichinose Y. c-kit mutation-positive advanced thymic carcinoma successfully treated as a mediastinal gastrointestinal stromal tumor: A case report. Mol Clin Oncol 2016; 4:527-529. [PMID: 27073655 DOI: 10.3892/mco.2016.752] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2015] [Accepted: 01/20/2016] [Indexed: 01/09/2023] Open
Abstract
Thymic carcinoma is an exceptionally rare tumor, which has a very poor prognosis, differing from thymoma. Although cytotoxic chemotherapy is commonly used to treat advanced thymic carcinoma, its effectiveness has not been found to be sufficient. There are several reports that thymic carcinoma also harbors an oncogenic driver mutation, similar to lung cancer. A patient with a c-kit mutation-positive thymic carcinoma received imatinib followed by sunitinib consecutively, which are both c-Kit inhibitors. Although the patient had achieved long-term disease control for 21 months, the primary lesion and pulmonary metastases had increased in size by November, 2014. Following failure of imatinib treatment, the patient received sunitinib, a multiple kinase inhibitor, initiated in December, 2014. Following administration of sunitinib, a computed tomography scan revealed a partial response and the disease was effectively controlled with continued sunitinib treatment for 6 months, up to June, 2015. The patient achieved long-term disease control (~27 months) with imatinib followed by sunitinib. The efficacy of consecutive molecular-targeted therapy for thymic carcinoma was demonstrated in this case. Therefore, thymic carcinoma with oncogenic driver mutations should be treated with molecular-targeted agents rather than with cytotoxic drugs, and it may be suitable to treat c-kit mutation-positive thymic carcinoma as a mediastinal gastrointestinal stromal tumor.
Collapse
Affiliation(s)
- Fumihiko Hirai
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Fukuoka 811-1395, Japan
| | - Makoto Edagawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Fukuoka 811-1395, Japan
| | - Shinichiro Shimamatsu
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Fukuoka 811-1395, Japan
| | - Ryo Toyozawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Fukuoka 811-1395, Japan
| | - Gouji Toyokawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Fukuoka 811-1395, Japan
| | - Kaname Nosaki
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Fukuoka 811-1395, Japan
| | - Masafumi Yamaguchi
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Fukuoka 811-1395, Japan
| | - Takashi Seto
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Fukuoka 811-1395, Japan
| | - Mitsuhiro Twakenoyama
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Fukuoka 811-1395, Japan
| | - Yukito Ichinose
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Fukuoka 811-1395, Japan
| |
Collapse
|
42
|
Hotta K, Sasaki J, Saeki S, Takigawa N, Katsui K, Takayama K, Nogami N, Shioyama Y, Bessho A, Kishimoto J, Tanimoto M, Kiura K, Ichinose Y. Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non–Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup Study Protocol. Clin Lung Cancer 2016; 17:75-9. [DOI: 10.1016/j.cllc.2015.08.004] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2015] [Accepted: 08/11/2015] [Indexed: 01/04/2023]
|
43
|
Tagawa T, Anraku M, Morodomi Y, Takenaka T, Okamoto T, Takenoyama M, Ichinose Y, Maehara Y, Cho BCJ, Feld R, Tsao MS, Leighl N, Bezjak A, Keshavjee S, de Perrot M. Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy. J Thorac Dis 2015; 7:1898-906. [PMID: 26716028 DOI: 10.3978/j.issn.2072-1439.2015.11.15] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
BACKGROUND To investigate the prognostic value of platelet-to-lymphocyte ratio (PLR) and create a new prognostic score in patients with malignant pleural mesothelioma (MPM) undergoing extrapleural pneumonectomy (EPP). METHODS Of 85 patients who underwent EPP for MPM over 10 years at Toronto General Hospital, 65 patients whose blood test results before initial therapy were available were retrospectively analyzed as a training cohort to identify and develop a prognostic score. Receiver operating characteristic (ROC) analysis was performed to examine cutoff values of hematologic parameters for survival. The prognostic score was externally validated in a cohort of 32 patients who underwent EPP for MPM over 13 years at two institutes in Japan. RESULTS In the training cohort, multivariate analysis confirmed sex (P=0.0053) and PLR (P=0.049) as independent predictors of overall survival. The prognostic score was established using sex and PLR. The score was defined as follows: female:male =0:1 point; PLR <215:>215=0:1 point. The patients were classified into three risk groups according to the sum of the points: risk 0 (0 point), 1 (1 point), and 2 (2 points). Median survival time of the patients in the training cohort according to the risk groups were not reached, 32.0 and 19.4 months for risk 0 (n=6), 1 (n=36) and 2 (n=23), respectively (P=0.0006). In the validation cohort, median survival time was not reached, 45.9 and 14.5 months for risk 0 (n=4), 1 (n=18) and 2 (n=10), respectively (P=0.0002). CONCLUSIONS The new prognostic score using PLR is simple and useful for predicting the prognosis of patients with MPM undergoing EPP. Further study should be done to examine the role of this scoring system to optimize treatment strategy.
Collapse
Affiliation(s)
- Tetsuzo Tagawa
- 1 Division of Thoracic Surgery, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada ; 2 Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan ; 3 Department of Thoracic Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan ; 4 Division of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan ; 5 Department of Radiation Oncology, 6 Department of Medical Oncology, 7 Department of Pathology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
| | - Masaki Anraku
- 1 Division of Thoracic Surgery, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada ; 2 Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan ; 3 Department of Thoracic Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan ; 4 Division of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan ; 5 Department of Radiation Oncology, 6 Department of Medical Oncology, 7 Department of Pathology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
| | - Yosuke Morodomi
- 1 Division of Thoracic Surgery, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada ; 2 Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan ; 3 Department of Thoracic Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan ; 4 Division of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan ; 5 Department of Radiation Oncology, 6 Department of Medical Oncology, 7 Department of Pathology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
| | - Tomoyoshi Takenaka
- 1 Division of Thoracic Surgery, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada ; 2 Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan ; 3 Department of Thoracic Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan ; 4 Division of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan ; 5 Department of Radiation Oncology, 6 Department of Medical Oncology, 7 Department of Pathology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
| | - Tatsuro Okamoto
- 1 Division of Thoracic Surgery, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada ; 2 Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan ; 3 Department of Thoracic Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan ; 4 Division of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan ; 5 Department of Radiation Oncology, 6 Department of Medical Oncology, 7 Department of Pathology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
| | - Mitsuhiro Takenoyama
- 1 Division of Thoracic Surgery, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada ; 2 Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan ; 3 Department of Thoracic Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan ; 4 Division of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan ; 5 Department of Radiation Oncology, 6 Department of Medical Oncology, 7 Department of Pathology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
| | - Yukito Ichinose
- 1 Division of Thoracic Surgery, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada ; 2 Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan ; 3 Department of Thoracic Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan ; 4 Division of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan ; 5 Department of Radiation Oncology, 6 Department of Medical Oncology, 7 Department of Pathology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
| | - Yoshihiko Maehara
- 1 Division of Thoracic Surgery, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada ; 2 Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan ; 3 Department of Thoracic Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan ; 4 Division of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan ; 5 Department of Radiation Oncology, 6 Department of Medical Oncology, 7 Department of Pathology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
| | - B C John Cho
- 1 Division of Thoracic Surgery, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada ; 2 Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan ; 3 Department of Thoracic Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan ; 4 Division of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan ; 5 Department of Radiation Oncology, 6 Department of Medical Oncology, 7 Department of Pathology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
| | - Ronald Feld
- 1 Division of Thoracic Surgery, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada ; 2 Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan ; 3 Department of Thoracic Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan ; 4 Division of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan ; 5 Department of Radiation Oncology, 6 Department of Medical Oncology, 7 Department of Pathology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
| | - Ming-Sound Tsao
- 1 Division of Thoracic Surgery, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada ; 2 Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan ; 3 Department of Thoracic Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan ; 4 Division of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan ; 5 Department of Radiation Oncology, 6 Department of Medical Oncology, 7 Department of Pathology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
| | - Natasha Leighl
- 1 Division of Thoracic Surgery, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada ; 2 Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan ; 3 Department of Thoracic Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan ; 4 Division of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan ; 5 Department of Radiation Oncology, 6 Department of Medical Oncology, 7 Department of Pathology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
| | - Andrea Bezjak
- 1 Division of Thoracic Surgery, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada ; 2 Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan ; 3 Department of Thoracic Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan ; 4 Division of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan ; 5 Department of Radiation Oncology, 6 Department of Medical Oncology, 7 Department of Pathology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
| | - Shaf Keshavjee
- 1 Division of Thoracic Surgery, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada ; 2 Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan ; 3 Department of Thoracic Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan ; 4 Division of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan ; 5 Department of Radiation Oncology, 6 Department of Medical Oncology, 7 Department of Pathology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
| | - Marc de Perrot
- 1 Division of Thoracic Surgery, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada ; 2 Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan ; 3 Department of Thoracic Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan ; 4 Division of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan ; 5 Department of Radiation Oncology, 6 Department of Medical Oncology, 7 Department of Pathology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
| |
Collapse
|
44
|
Ohba T, Toyokawa G, Osoegawa A, Hirai F, Yamaguchi M, Taguchi KI, Seto T, Takenoyama M, Ichinose Y, Sugio K. Mutations of the EGFR, K-ras, EML4–ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma. Surg Today 2015; 46:1091-8. [DOI: 10.1007/s00595-015-1295-z] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2015] [Accepted: 11/02/2015] [Indexed: 01/27/2023]
|
45
|
Nosaki K, Inamasu E, Shimamatsu SI, Yoshida T, Toyokawa G, Hirai F, Yamaguchi M, Seto T, Takenoyama M, Ichinose Y. Systemic chemotherapy for pulmonary pleomorphic carcinoma. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv472.03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Fukuda M, Suetsugu T, Shimada M, Kitazaki T, Kishimoto J, Takayama K, Sugio K, Semba H, Nakanishi Y, Ichinose Y. Prospective study of UGT1A1*27 polymorphism for irinotecan therapy: result of lung oncology group in Kyushu (LOGiK1004B). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv472.83] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
47
|
Hirai F, Shimamatsu S, Toyokawa G, Yoshida T, Nosaki K, Yamaguchi M, Seto T, Takenoyama M, Ichinose Y. Management of toxicities and dose reduction/interruption of afatinib for EGFR mutated non-small cell lung cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv472.140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
48
|
Osoegawa A, Kometani T, Fukuyama S, Hirai F, Seto T, Sugio K, Ichinose Y. Prognostic Factors for Survival after Resection of Pulmonary Metastases from Colorectal Carcinoma. Ann Thorac Cardiovasc Surg 2015; 22:6-11. [PMID: 26289631 DOI: 10.5761/atcs.oa.14-00345] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
PURPOSE As chemotherapy has improved, the survival of patients with metastatic colorectal carcinoma has reached up to 2.5 years. Many of these patients experience pulmonary metastases; however, the prognosis after pulmonary metastasectomy is not satisfying. In this study, we analyzed the prognostic factors for survival in patients who underwent pulmonary metastasectomy. METHODS Eighty-seven patients with colorectal carcinoma received pulmonary metastasectomy. The pathological status of the primary tumor, outcome of the pulmonary metastasectomy, disease-free interval, perioperative carcinoembryonic antigen (CEA) level and history of liver metastases were assessed. RESULTS The five-year survival was 42.5% after pulmonary metastasectomy. A univariate analyses revealed that the CEA level (p = 0.043) and the number of pulmonary metastases (p = 0.047) were prognostic factors for survival. The CEA level was an independent prognostic factor in a multivariate analysis (relative risk = 2.01, p = 0.037). Among cases with elevated preoperative CEA levels, those whose CEA level normalized after metastasectomy had a better prognosis compared with those whose CEA level decreased but was still high, or whose level increased after metastasectomy (median survival time of 41.8 months compared with 28.1 or 15.7 months, respectively p = 0.021). CONCLUSION The CEA level can be a predictive marker for the prognosis in patients with pulmonary metastases from colorectal carcinoma.
Collapse
Affiliation(s)
- Atsushi Osoegawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Fukuoka, Japan
| | | | | | | | | | | | | |
Collapse
|
49
|
Yamaguchi M, Furuya A, Edagawa M, Taguchi K, Shimamatsu S, Toyokawa G, Toyozawa R, Nosaki K, Hirai F, Seto T, Takenoyama M, Ichinose Y. How should we manage small focal pure ground-glass opacity nodules on high-resolution computed tomography? A single institute experience. Surg Oncol 2015; 24:258-63. [PMID: 26298200 DOI: 10.1016/j.suronc.2015.08.004] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2015] [Revised: 07/24/2015] [Accepted: 08/09/2015] [Indexed: 11/25/2022]
Abstract
BACKGROUND Although the detection of pure ground-glass opacity (p-GGO) nodules on high-resolution chest computed tomography (HRCT) often implies a diagnosis of lung adenocarcinoma, the management of p-GGO nodules remains under discussion. OBJECTIVE To assess the correlation between the radiological and pathological diagnoses of small p-GGO on HRCT. PATIENTS AND METHODS This is a single-institution retrospective study. We analyzed 89 consecutive patients, including 33 patients with resected p-GGO nodule(s) equal or less than 20 mm in maximal diameter on axial images of HRCT. RESULTS Thirty-nine patients underwent locoregional treatment (Treatment group), including surgical resection in 33 and stereotactic body radiation therapy in six. The remaining 50 patients were observed (Observation group) using periodic chest HRCT. The median follow-up time was 30.4 (4.9-102.5) months in the Treatment group and 44.8 (0.4-1125.8) months in the Observation group. During the follow-up period, the p-GGO nodules increased in size in eight patients over a median of 20.6 (12.1-50.6) months, with increased attenuation in three patients over a median of 20.6 (12.1-50.6) months, and either decreased in size or disappeared in four patients over a median of 6.9 (2.0-11.2) months. Thirty-three patients with 47 nodules underwent surgical resection, including 41 adenocarcinomas, one neuroendocrine tumor, three cases of atypical adenomatous hyperplasia and two benign lesions. The frequency of invasive adenocarcinoma was higher among the larger p-GGO nodules. CONCLUSIONS Careful observation and decision making with respect to the timing of intervention in cases of p-GGO nodules are warranted.
Collapse
Affiliation(s)
| | - Akio Furuya
- Department of Diagnostic Imaging and Nuclear Medicine, National Kyushu Cancer Center, Japan
| | - Makoto Edagawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, Japan
| | - Kenichi Taguchi
- Department of Pathology, National Kyushu Cancer Center, Japan
| | | | - Gouji Toyokawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, Japan
| | - Ryo Toyozawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, Japan
| | - Kaname Nosaki
- Department of Thoracic Oncology, National Kyushu Cancer Center, Japan
| | - Fumihiko Hirai
- Department of Thoracic Oncology, National Kyushu Cancer Center, Japan
| | - Takashi Seto
- Department of Thoracic Oncology, National Kyushu Cancer Center, Japan
| | | | - Yukito Ichinose
- Department of Thoracic Oncology, National Kyushu Cancer Center, Japan
| |
Collapse
|
50
|
Iwamoto Y, Mitsudomi T, Sakai K, Yamanaka T, Yoshioka H, Takahama M, Yoshimura M, Yoshino I, Takeda M, Sugawara S, Kawaguchi T, Takahashi T, Ohta M, Ichinose Y, Atagi S, Okada M, Saka H, Nakagawa K, Nakanishi Y, Nishio K. Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II–IIIA Non–Small Cell Lung Cancer. Clin Cancer Res 2015; 21:5245-52. [DOI: 10.1158/1078-0432.ccr-14-3160] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2014] [Accepted: 07/12/2015] [Indexed: 11/16/2022]
|